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ABSTRACT 
According to the Centers for Disease Control, the geriatric population of ≥65 
years of age will increase to 51.5 million in 2020; 40% of white women and 13% of 
white men will be at risk for fragility fractures or fractures sustained under normal stress 
and loading conditions due to bone disease, leading to hospitalization and surgical 
treatment. Fracture management strategies can be divided into pharmaceutical therapy, 
surgical intervention, and tissue regeneration for fracture prevention, fracture 
stabilization, and fracture site regeneration, respectively. However, these strategies fail to 
accommodate the pathological nature of fragility fractures leading to unwanted side 
effects, implant failures, and non-unions.  
Compromised innate bone healing reactions of patients with bone diseases is 
exacerbated with protective bone therapy. Once these patients sustain a fracture, bone 
healing is a challenge especially when fracture stabilization is unsuccessful. Traditional 
stabilizing screw and plate systems were designed with emphasis on bone mechanics 
rather than biology. Bone grafts are often used with fixation devices to provide skeletal 
continuity at the fracture gap. Current bone grafts include autologous bone tissue and 
donor bone tissue; however, there is insufficient quality and quantity demanded by 
fragility fractures sustained by high-risk geriatric patients and patients with bone 
diseases. Consequently, bone tissue engineering strategies are advancing towards 
functionalized bone substitutes to resolve shortages in fracture reconstruction while 
effectively mediating bone healing in normal and diseased fracture environments.  
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In order to target fragility fractures, fracture management strategies should be 
integrated for a synchronized treatment of prevention without hindrance to bone 
regeneration and fracture stabilization with bioactive bone substitutes designed for the 
pathological environment. However, the clinical outcome of these materials must be 
predictable within various disease environments. Initial development of a targeted 
treatment strategy should focus on simulating physiological in vitro bone environment to 
predict clinical effectiveness of engineered bone while understanding cellular responses 
due to the alternative agents and bioactive scaffolds. An in vitro testing system can be the 
predicate to reducing implant failures and non-unions in fragility fractures. 
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The number of bone grafting procedures performed annually was estimated, in 
2001, to be 500,000 in the US and over 2.2 million worldwide, with an expected increase 
of 13% per year exceeding the procurement of donor tissue [5-8]. The bone graft of 
choice for surgeons is autologous bone tissue, harvested from the patient’s own bone, 
commonly from the iliac crest. However, for patients with bone diseases, the natural 
regenerative capability of bone is greatly hindered and further exaggerated with bone 
protective drug therapies. The preferred alternative to an autograft is an allograft obtained 
from donor tissue; however, limited donor supply has driven the development of 
substitute bone biomaterials composed of polymers, ceramics, and their composites. 
Bone tissue engineers have innovated and investigated a vast array of biomaterials 
to mimic the mechanical, physiochemical, and biological properties of bone.  
Additionally, chemical, molecular, and cellular mediators have been incorporated into 
biomaterials to stimulate and enhance the bone healing cascade [11-14]. Early testing of 
enhanced biomaterials are limited to in vitro characterizations of monocultures and co-
cultures that are inconsistent in design and mimicry to the natural bone environment. 
With advance in understanding cellular and molecular biology of bone, a better in vitro 
culture can be developed to be able to predict clinical outcome of the biomaterial for an 
expedited journey to clinical applications. 
An established standard in vitro multicellular culture system simulating aspects of 
bone cell pathology will emphasize and overcome the pathological limitations of fracture 
healing. A greater understanding of bone healing under pathological conditions have 
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allowed researchers to design cellular bone replacements that significantly reduce non-
healing fractures. Hence, a co-culture test system with relevant cell ratio to simulate 
pathological conditions can account for specific environments or exaggerate the 
anomalies. The proposed test system will utilized precursor osteoclasts and osteoblasts to 
understand bone cell differentiation on commercially available bone substitute ChronOS 
granules. The precursor cells are cultured at varying cell ratios of 1:1, 1:10, 1:100 
(precursor osteoclast:osteoblast) to simulate pathological bone cell conditions in order to 
predict clinical outcome of ChronOS as a treatment option for patients with abnormal 
bone cell activity in bone formation and resorption of the material. The overall research 
objective is to establish a standard co-culture condition using murine RAW monocytes 
and D1 stromal cells at the specified cell ratios to elicit characteristic metabolic activity, 
gene expression, and protein production native to bone formation. To translate research 
concepts to the K-12 community, a teaching module was designed to introduce middle 
and high school students to bone tissue engineering as a possible career aspiration within 
biomedical engineering. To accomplish the overall objectives, four specific aims were 
recognized as follows: 
Aim 1: Determine co-culture cell ratio for RAW:D1 to differentiate into 
osteoclast:osteoblast 
Aim 2: Determine necessity for RANK ligand for osteoclastogenesis in presence of 
osteoblasts  
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Aim 3: Determine multicellular culture with co-culture of RAW:D1 for 
osteoclast:osteoblast differentiation in presence of indirect culture with 
adipocytes 
Aim 4: Develop a workshop lesson plan and hands-on activity to effectively 
introduce bone tissue engineering to young students by demonstrating bone 
biology and implant development 
As detailed in Chapter 2, Aim 1 study was designed to simulate the natural bone 
environment, considerations for cell ratio were taken into account to demonstrate the 
differences in cellular interaction, communication, and activity. The culture system used 
3D ChronOS bone granules (Synthes) to simulate the complex architecture of bone 
extracellular matrix. Precursor bone cells were seeded at three RAW:D1 ratios (1:1, 1:10, 
1:100) to culture for 35 days under osteogenic condition to monitor cellular 
differentiation and activity. Analysis of relative gene expression and protein levels were 
quantified to determine which cell ratio follows physiological behavior at key stages of 
maturation. Visual observations via fluorescent microscopy confirmed cell attachment, 
proliferation, and morphology. 
Experimental details for Aim 2, as detailed in chapter 2, was conducted 
simultaneously with Aim 1 by including an additional culture condition of osteogenic 
medium supplemented with RANK ligand. Osteoblast and osteoclast maturation will be 
monitored for relative gene expression and protein production. 
Aim 3, detailed in Chapter 3, focused on the multi-cellular culture of osteoclasts 
and osteoblasts in the presence of differentiated adipocytes to determine the influence of 
 4 
adipocytes on bone cell activity. To simulate direct communication of differentiating 
precursor osteoclasts with osteoblasts and indirect communication with adipocytes, 
Netwell inserts were used to suspend the co-culture within a well compartment with 
adipocytes. Adipogenic differentiation of D1 cells on well-plates began 7 days prior to 
tri-culture simulation. Seeding of co-culture of RAW:D1 occurred 3 days prior to tri-
culture for 14 days. Information on cell ratio gleaned from Aim 1 and Aim 2 were 
implemented in the experimental setup for Aim 3 in simulating normal bone cell 
interactions. By applying the co-culture to the tri-culture system with adipocytes, effects 
of adipogenic factors (lipids, hormones) on osteoclast and osteoblast activity were 
examined with gene expression and protein production. Behavior characterization 
methods for osteoclasts and osteoblasts were duplicated from Aims 1 and 2 with the 
addition of adipogenic markers. 
The educational outreach workshop from Aim 4, as detailed in Chapter 4, 
introduced bone tissue engineering technologies to a group of girl scouts and high school 
students through a presentation, a hands-on activity, and an interactive communication. 
The teaching module incorporated biomedical engineering, bone biology, and medical 
devices for fracture management. The teaching module was implemented during two 
separate events with other teaching modules that also focused on introducing engineering 
and science to the students. Hence, the biomedical engineering teaching module was 
limited to 1-hour. The presentation provided an overview of bone physiology, various 
bone diseases, and orthopedic implants ending with a problem statement for the students 
to address in their hands-on activity. With the information given to them, the students 
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were challenged to strategize, implement, and test a plan to stabilize a simulated normal 
fracture and an osteoporotic fracture. Instructions required the girls to follow the 
development scheme of brainstorming, designing, prototyping, and testing. The hands-on 
activity will be made into a kit consisting of the tools, simulated fractures (cardboard 
tubes filled with styrofoam and insulation foam), screws, and a metal or plastic mending 
plate as internal fixation screw and plate system. Effectiveness and influence of the 
demonstration were measured by social cognitive theory pre- and post- survey questions, 
including rank based and open-ended questions. Due to the time constraint for each group 
of students, measurements of career interest incorporated engineering, science, and math 
in general rather than a focus on biomedical engineering. 
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CHAPTER ONE  
INTRODUCTION 
1.1 Clinical Significance 
Tissue engineering and regenerative medicine emerged to resolve shortages in 
tissue transplantation for treatment of damaged tissues and organs. The theory is that 
engineered biotechnologies incorporating biomaterials, chemical mediators, and stem 
cells can produce functional tissues that repair and prevent the loss of damaged tissues. 
Many advances have been possible due to increased understanding and discoveries of 
human pathology at the tissue to molecular level. Innovations in medicine are driven by 
the objective to decrease patient suffering and increase longevity, especially as the 
population and life expectancy grow. However, as the past generations age and the future 
generations become more active, the frequency of injuries and diseases will increase 
dramatically. The Centers for Disease Control has predicted that, in 2020, over 51.5 
million people in the United States will be ≥65 years old, while the United States Census 
Bureau estimates the world population will reach 8 billion people. The rise in population 
will amplify the strain on the medical industry to maintain a healthy population. Since 
traumatic injuries can result in tissue or organ failure, tissue transplantation will become a 
necessity. There are many complications associated with tissue transplantation and a 
major challenge is obtaining viable donor tissue. Consequently, tissue engineering and 
regenerative medicine is evolving to develop patient-specific and biologically functional 
tissues.  
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Bone grafts are the second most transplanted tissues, exceeded only by blood [4]. 
Currently, over 500,000 bone graft implantations occur annually in the United States, 
with surgeons preferentially using gold standard autografts, opting for allografts as a 
second choice, to treat large bone fractures and defects. Further considerations of fracture 
severity, fracture location (long or flat bone), and bone type (cancellous or cortical) are 
required to choose the optimal graft to induce an effective bone healing response [5]. 
However, autografts and allografts are also the top choices for patients with bone diseases 
and impaired healing reactions. Normal healing time for cortical (compact) bones are 
much longer than cancellous (spongy) bones due to the differences in bone density, but 
bones with impaired healing will, at best, heal at the slowest rate or, at worst, have 
incomplete healing. Even though there are limitations to bone grafting, especially for 
patients with degenerative bone diseases, both cortical and cancellous autografts and 
allografts are used.  
Autografts and allografts bridge the gaps at fracture sites to provide skeletal 
continuity and encourage the innate bone healing cascade. The transplanted grafts are 
considered necrotic tissues that serve as the template for bone regeneration. The bone 
healing and repair reactions start with the formation of a hematoma to induce 
revascularization and recruit progenitor bone cells to the site of injury within 2 weeks. 
Bone cells then form new woven bone to stabilize and establish skeletal continuity at the 
fracture, which can take 6 weeks to 6 months. The woven bone is eventually remodeled 
into mature lamellar bone, years following the implantation [5, 6]. The rate and success 
of bone repair and regeneration depends on the quality and type of grafts transplanted. 
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Autologous and donor bone tissue can be cortical (compact) or cancellous (spongy), the 
two natural organizations and architectures of bone. Cortical and cancellous graft 
transplantations will each induce a different healing response and graft integration with 
host bone tissue (osteointegration) [6]. Cortical grafts have low porosity that results in 
minimal neo-vascular formation, resorption of the graft before woven bone regeneration, 
and remodeling of the graft. Due to the lack of vascular infiltration and density of the 
graft, osteointegration is limited to the exterior where surface bone resorption provides 
space for woven bone formation. Consequently, 50-90% of residual necrotic graft tissues 
remains and can diminish the mechanical integrity of bone at the fracture gap. Cancellous 
grafts, on the other hand, have high porosity to induce ingrowth of new blood vessels, 
new woven bone, and complete remodeling of the graft in which lamellar bone replaces 
both the woven bone and graft material [6]. Clearly, if not for the limited quantity of 
autografts and low quality of allografts, the graft of choice is a cancellous graft.  
Autografts are bone tissue retrieved from the patient’s own bone through a 
surgical extraction procedure, most commonly at the iliac crest. It is thought that 
transplantation of the bone will provide viable tissue with biological function; however, 
the removal will damage the cellular components, tissue continuity, and the tissue’s 
regenerative ability. Compared to allografts and donor bone tissue, autografts increase 
patient risk during extraction procedures but have enhanced graft-to-tissue integration 
(osteointegration) and compressive strength. The autograft harvesting causes 
complications in 8-20% of all patients, including blood loss, nerve damage, artery 
damage, chronic pain, tissue necrosis, and infection [4]. For patients with bone disease, 
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autograft extraction and implantation significantly increases healing complications due to 
decreased bone quality and regeneration ability; hence, allografts are the alternative of 
choice. 
Allograft is donor bone tissue that has been processed to remove all cellular, 
bacterial, and viral components to eliminate immune response and disease transmission 
[7]. Even though processing significantly compromises osteogenic and mechanical 
properties of the tissue, it is the material of choice for 35% of all grafting procedures 
because of its availability, shelf-life, and customizable type and size [8]. The 
physiochemical properties of allografts are different for fresh, frozen, or freeze-dried 
allografts. Fresh allografts are rarely used because of the extended time required for 
screening to prevent disease transmission. Processed allografts can be frozen at -60°C or 
freeze-dried to decrease enzymatic activity and immune response or destroy all cellular 
components and completely eliminate immune responses. These processing methods 
decrease the tissue’s ability to recruit progenitor bone cells (osteoinduction) and to 
mediate differentiation of bone cells. However, with the introduction of bone 
morphogenic protein (BMP) into allografts, a 15-fold increase in allograft implantation 
occurred over the past decade [4, 9]. 
With the increased frequency of bone fractures and with the low and costly 
allograft supply, surgeons are more frequently opting for bone substitute materials. The 
development of substitute biomaterials for bone constructs will allow customizable 
mechanical and biological properties native to bone. Eventually, enhancements will 
incorporate osteoinductive and osteoconductive properties for constructs, specifically for 
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mediating bone healing in diseased bone. Synthetic and natural biomaterials with 
physicochemical properties similar to the inorganic and organic components of bone are a 
focus of ongoing investigation. The design and construction of a temporary 3D template 
that mimics the inherent architecture and compressive strength are ongoing challenges 
within the evolving field of bone tissue engineering. Furthermore, the future direction of 
substitute bone construct design and development should target fragility fractures in 
diseased bone. 
1.2 Background in Bone Tissue Engineering 
Before regenerative medicine and bone grafts were developed in widespread 
form, large segmental bone defects lead to amputations. However, recent advances in 
fixation devices, bone tissue engineering, and surgical procedures have lead to restoration 
options for bone and limb tissue [9]. The first documented bone tissue engineering 
attempt was in 1668 when bone grafting was first attempted and evolved into a 
multidisciplinary science that has facilitated the development of biotechnologies and 
management procedures for treating various bone defects and diseases [6]. By 
investigating mechanisms of bone pathology, researchers are able to map physiological 
repair and remodeling reactions and pathways in bone metabolism. A thorough 
understanding of bone tissue and bone remodeling is essential to designing regenerative 
solutions that maintain bone integrity and target degenerative bone diseases.  
1.1.1 Bone Composition and Structure 
At the surface, bone looks simple and non-viable but at the microscopic level the 
complexity and dynamic nature of bone matrix and bone cells are evident. Bone tissue 
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harnesses an innate ability to self heal from micro- and macro-fractures throughout a 
person’s lifetime, while providing structural mechanics, movement, and protection. The 
206 bones in the body assemble into an upright skeleton to support and protect all other 
soft tissues. The irregular shapes of bones have been optimized for ease of movement at 
each joint, transmission of external loads, and protection for each vital organ. Bone is 
composed of inorganic (hydroxyapatite) and organic matrix (collagen and proteoglycans) 
organized into a 3D structure of Haversian and Volkmann canals.  
The architectural organization of bone can be classified into cancellous and 
cortical, according to structural density and porosity. Bone matrix is a combination of 
highly compressive hydroxyapatite, crystalline and highly ductile collagen, and 
proteoglycans; this combination allows the tissue to withstand varying loads of tension, 
compression, and shear encountered by the body. To further reinforce structural integrity, 
the matrix is arranged into parallel or circumferential lamellae to form cancellous or 
cortical bone, respectively. Due to the longitudinal organization, bone is an anisotropic 
material with higher resistance to longitudinal forces than latitudinal. 
Cortical bone serves as the outer lining for most bones because it is stronger and 
heavier than cancellous bone. This highly compact bone with <10% porosity is made of 
longitudinal concentric lamellae (layers), with interstitial and circumferential lamellae for 
compressive strength and load transmission. Within compact matrix, there is a network of 
Haversian and Volkmann canals through which vascular structures pass, as well as 
lacunae-containing osteocytes (mature bone cells). The compressive modulus of cortical 
bone is ~17.0 GPa in the longitudinal direction, ~11.5 GPa in the transverse direction, 
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and ~3.3GPa in shear [10]. Cancellous bone, on the other hand, has a parallel lamellar 
organization that forms interconnected struts called trabeculae. Enclosed by cortical bone, 
the trabecular organization of cancellous bone has a density range of 5-90% depending 
on location, resulting in much lower weight and compressive moduli of 291-445 MPa. 
However, these lightweight struts serve to redistribute load more effectively along the 
bone while the interconnected pores store bone marrow and a vascular network [10]. 
These two types of bone are then arranged in various configurations to form long 
segmental, flat, or irregular bones and serve their specific function of locomotion or 
protection. Since bone is a living tissue, it is composed of specialized cells with innate 
capacities to maintain bone integrity by continually remodeling old bone and repairing 
damaged bone. 
These structural organization and mechanical properties are challenging to 
integrate in bone substitute constructs due to material and fabrication limitations of 
current technologies. Innovative bone construct designs have included hardened sponges, 
sintered microspheres, fibrous matrices, and rapid prototyped woven matrices [11-16]. 
1.1.2 Bone Cellular Components 
At the core of hollow long bones lies bone marrow, a source for skeletal 
progenitor cells that have been shown to differentiate along osteoblastic, adipogenic, and 
chondrogenic lineages [17]. Friedenstein and coworkers discovered bone marrow during 
their investigation of bone’s innate healing capacity as related to stem/progenitor cell 
involvement and availability [17-19]. Further characterization of heterogeneous mixtures 
of bone marrow stem and progenitor cells has lead to understanding the differentiation 
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potential of the multipotent adult progenitor cells, mesenchymal stem cells, bone marrow 
stromal cells, and hematopoietic stem cells [17].  
The cellular components of bone are under highly regulated coordination in 
response to internal signaling and external mechanical loading. The resorption and 
production of bone matrix are the results of activated osteogenic cells, differentiated from 
mesenchymal stem cells (MSC) and hematopoietic stem cells in response to cytokines 
and growth factors (Figure 1.1). Recruited hematopoietic stem cells, specifically 
monocytes, are directed by macrophage colony stimulating factor (M-CSF), receptor 
activator of NFĸ (RANK), and RANK ligand (RANKL) to fuse into inactive 
Figure 1.1. Differentiation of osteoblasts (A) and osteoclasts (B) in response to 
internal cytokines and molecular mediators. 
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multinucleated osteoclasts. Further interactions of RANK, a surface receptor of 
osteoclastic cells, and RANKL, a surface marker of osteoblasts, will polarize osteoclasts 
to develop resorptive ruffled borders that attach to the bone matrix. The ruffled borders 
enclose an area marked for resorption and the secretion of protolytic enzyme cathepsin K 
and tartrate-resistant acid phosphatase (TRAP) for the degradation of the unwanted bone 
matrix. However, osteoprotegerin (OPG) serves as the negative feedback that interferes 
with RANKL and RANK signaling to inhibit and regulate osteoclast polarization and 
activation. The enzymatic resorption process creates pits on the bone surface called 
“Howship’s lacuna”, which are coated with cytokines and factors to recruit osteoblastic 
cells to the excavation site to deposit new bone at the eroded surface [1]. Osteoblasts 
differentiate from mesenchymal stem cells, with transcription factor signaling via Runx2, 
osterix, and β-catenin. The progenitor cells differentiate into preosteoblasts, then 
immature osteoblasts, expressing high levels of osteopontin. Osteoblast maturation 
continues under the control of Runx2.  During this time the mature osteoblasts release 
high levels of alkaline phosphatase (ALP) and express osteocalcin, as mineralization 
occurs and new bone matrix is deposited [20]. As new extracellular matrix composed of 
the inorganic and organic phase of bone accumulates, osteoblasts become embedded 
within the matrix, leading to their differentiation into osteocytes; subsequently, these 
cells remain latent in the lacunae to monitor the health of the bone. Osteocytes are able to 
communicate and interact directly with vasculature and other osteocytes because of their 
numerous cytoskeletal extensions that travel along microscopic channels called canaliculi 
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[1]. Consequently, when there is a disturbance in bone integrity, osteocytes initiate bone 
healing reactions.  
A recent discovery of fatty acid secretions mediating bone mineral density has led 
investigators to study the influence of adipocytes, or fat cells, on bone formation [21, 22]. 
Adipocyte secretions have been shown to regulate the activity of both osteoclasts and 
osteoblasts. Adipocytes are found in close proximity to bone cells in brown and white 
marrow fat and their fatty acid secretions can diffuse into active bone cells undergoing 
bone remodeling. Studies have shown that stearic and palmitic acids decrease the 
expression of alkaline phosphatase (ALP), which is an indicator of osteoblast 
mineralization, while linoleic acids increase the expression of ALP [21, 23]. However, 
fatty acids such as dexamethasone and prostaglandin E2 promote osteoclast resorption. 
This regulation by fatty acids establishes a direct relationship of aging bone with 
increased fatty marrow to low bone mineral density in geriatric patients [24].  
As bone cells differentiate under high regulation, favorable conditions, and 
mediators, bone remodeling and healing will proceed with a balance in bone degradation 
and deposition for optimal bone integrity and health. Unfortunately, traumatic injuries 
and cellular imbalances occur which challenge the innate self-healing capacity and the 
regulated feedback mechanisms, respectively. 
1.1.3 The Bone Healing Process and Bone Cell Communication 
Bone is the infrastructure of the body, possessing mechanical and biological 
properties vital for support, protection, growth, and immunity. However, like most tissues 
in the body, bone has a physiological carrying capacity, namely its mechanical strength. 
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When skeletal continuity is disrupted due to excessive stress and loading, bone can repair 
and heal itself without producing a scar. The physiological healing process is extensive, 
involving a vast network of cellular signals to recruit and differentiate progenitor stem 
cells to osteoclasts and osteoblasts in order to resorb and deposit new bone [25]. Since 
bone serves as the structural support for the body, healing and repairing reactions are 
impacted by the mechanical stability and the biological environment of the damage or 
fracture site, along with the severity of injury of the surrounding soft tissues. After an 
assessment of the damage, primary or secondary healing reactions will occur.  
Primary fracture healing via a “cutting cone” occurs with absolute stability, 
requiring no external callus bridging. However, if the fracture gap exceeds 200µm, 
osteoclasts are hindered from constructing the “cutting cone”, which can delay bone 
union. The “cutting cone” is the organization of osteoclasts that tunnel across the fracture 
line to resorb bone while osteoblasts are recruited to deposit new bone and reconstruct the 
bone union [5]. For secondary bone healing, there is a strain between the fracture surfaces 
that necessitates the formation of a callus bridge to stabilize the fracture for ossification. 
This type of healing is typical for patients with bone graft implantations and/or internal 
fixation devices. There are four phases to secondary healing, all of which are regulated at 
the cellular and molecular level for neo-vascularization and bone regeneration. The 
process starts with non-specific signaling to respond to the trauma-related inflammation 
and hematoma formation, proceeds to fracture bridging via soft callus, then to hard callus 
formation, and finally to specific regulation of bone remodeling [1, 5, 25-29]. Even 
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though the repair process is highly regulated, participating cellular and molecular 
components contribute at each phase, overlapping as seen in Figure 1.2.   
Phase 1: Inflammation 
Fractures due to trauma also result in disruption of the surrounding tissues, vasculature, 
and bone integrity. This trauma causes an immediate, nonspecific response in which the 
pooling of blood and accumulation of inflammatory cells at the injury site form a 
hematoma encased by surrounding tissues. The inflammatory cells, such as degranulated 
platelets, macrophages, monocytes, and lymphocytes, are the first responders to form a 
blot clot and remodel the hematoma into granulation tissue as macrophages and giant 
cells remove necrotic cells. Cellular coordination is conducted through the secretion of 
cytokines and growth factors, such as vascular endothelial growth factors (VEGF), 
Inflammatory cells 
Chondrocytes 
Mesenchymal stem cells Osteoblasts 







Hard callus formation 
Phase 4: 
Remodeling 
Figure 1.2. Timeline of cellular contributors during the four phases of bone remodeling. (Adapted from 
Schindeler et al., 2008, and Carano and Filvaroff [1, 2]). 
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platelet-derived growth factor (PDGF), and others seen in Table 1.1, to mediate 
recruitment of more inflammatory cells as well as chondrogenic and osteoprogenitor cells 
[1, 29].  
  
Phase 2: Soft callus (fibrocartilage) formation 
Once chondrogenic and fibroblastic cells reach the bone fracture, endochondral 
ossification occurs as a fibrocartilage soft callus is formed. Since the fracture site is 
mechanically unstable, a soft callus provides stability and a template for primary bone 
formation. Recruited mesenchymal progenitor cells differentiate into chondrocytes to 
produce the cartilaginous matrix that merges with fibrous tissue produced by fibroblasts 
to establish a continuous bone bridge [1]. Bone morphogenetic protein and fibroblast 
Table 1.1. Molecular Contributors to Bone Healing 
Pro-inflammatory cytokines 
and growth factors 
Pro-osteogenic factors Angiogenic factors 





Platelet-derived growth factor 
(PDGF) 
Receptor activator of NFκB 
(RANK) 
BMPs 
Fibroblast growth factor-2 
(FGF-2) 
RANK ligand (RANKL) FGF-1 
Vascular endothelial growth 
factor (VEGF) 
BMPs TGF-β 
Macrophage colony stimulating 
factor (M-CSF) 
M-CSF Angiopoietin I and II 
Interleukin-1 and -6 (IL-1, IL-
6) 
Osteoprotegrin (OPG)  
Bone morphogenetic proteins 
(BMPs) 
  




growth factor (FGF) are the major signaling molecules for ossification [30]. 
Angiogenesis, or the formation of new blood vessels, occurs concurrently with 
ossification under the control of VEGF and angiopoietin I and II [26]. However, VEGF 
expression is dependent on the expression of Runx2 (early osteoblastic marker) by 
osteogenic cells activated for hard callus formation [1]. 
Phase 3: Hard callus formation 
This phase is the major component of osteogenesis and includes a high level of 
osteoblast matrix deposition onto the soft callus template, following which the 
mineralized bone matrix converts the soft callus into a hard callus or woven bone. 
Activated osteoblasts are recruited with osteogenic factors from the super family of 
transforming growth factor-β (TGF-β), such as BMP-differentiating osteoprogenitor cells 
recruited during hematoma formation. With the help of vascular networks, 
osteoprogenitor cells and their differentiation signals are able to infiltrate the soft callus 
to efficiently mineralize the woven bone [1, 30]. However, innate bone repair continues 
to reestablish structural organization of native bone and converts woven bone into 
lamellar bone. 
Phase 4: Bone remodeling 
The conversion to lamellar bone requires resorption of woven bone by osteoclasts. 
Osteoclasts differentiated from monocytes remodel the woven bone hard callus into 
lamellar bone in the appropriate cortical or cancellous configuration. Monocytes are first 
recruited to the site for remodeling, then the cells mature into polarized osteoclasts and 
adhere to the mineralized surface. The attached ruffled borders of osteoclasts secrete 
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proteases such as cathepsin K and tartrate-resistant acid phosphatase (TRAP) to degrade 
the woven bone. The resorption process creates pits on the bone surface called 
“Howship’s lacuna” that recruit and activate osteoblasts to regenerate new bone at the 
eroded surface. Cytokines such as macrophage colony stimulating factor (M-CSF) 
regulate osteoblast bone mineralization, while receptor activator of NFĸ (RANK) and 
RANK ligand (RANKL) activate osteoclast resorption and osteoprotegerin (OPG) to 
inactivate resorption as needed [1, 25, 29, 31-33]. The bone remodeling phase is a 
juxtaposition of osteoblast anabolism and osteoclast catabolism of bone matrix [1].  
The four phases of bone healing occur in conjunction with each other with no real 
separation between the end of one phase and the start of another. The balanced reaction is 
highly regulated and coordinated at the cellular and molecular level to produce effective 
healing responses. Healing rates are dependent on the implanted grafts (cortical or 
cancellous), the health of the patient, and location and severity of the fracture.  
1.3 Bone Pathology 
Bone healing reactions of adults and children suffering with bone diseases and 
defects are compromised, leading to complications with graft implantation and internal 
fixation treatments. When imbalances occur within the highly regulated bone repair and 
remodeling processes, bone diseases arise from abnormal bone cell activity and 
metabolism. The majority of bone diseases are due to overactive or inactive osteoclasts, 
resulting in decreased bone density or increased bone mass, respectively. The most 
diagnosed bone disease is osteoporosis, or low bone density, a degenerative disease 
affecting the aged population. The onset of osteoporosis is osteopenia, or the gradual loss 
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of bone mass associated with high osteoclast resorptive activity exceeding osteoblastic 
regenerative activity [34]. Risk factors for developing osteopenia and osteoporosis 
include low physical activity and vitamin D deficiency, which are physical and chemical 
stimulators for bone remodeling. The combination of aging and low physical activity will 
increase osteoporosis risk, since factors will increase marrow fat concentration which can 
interfere with osteoblast activity while promoting osteoclast metabolism [35-37]. Johnell 
and Kanis estimated the world burden of osteoporotic fractures to be 9 million 
occurrences in the year 2000, with 61% affiliated with women over the age of 50. The 
most common fractures incurred by osteoporotic patients are vertebral fractures which 
can be fatal if not debilitating [38]. Current pharmaceutical agents for osteoporosis target 
and interfere with RANK/RANKL and/or induce the OPG signaling pathway to prevent 
osteoclastogenesis (osteoclast differentiation and activation) [3].  
At the other extreme, impairment of osteoclast resorption or osteoclastogenesis 
will result in osteopetrosis, sclerosteosis, or Paget’s disease conditions, i.e. high bone 
mass due to osteoblastic bone matrix construction in the absence of osteoclastic bone 
matrix destruction [3]. Osteopetrosis is a rare hereditary genetic disease, involving 
osteoclastogenesis inhibition and associated low supply of bone marrow, osteosclerosis, 
short stature, brittle bones, and even cranial nerve compression due to the closure of the 
cancellous bone cavities [39, 40]. Sclerosteosis is caused by interference of 
osteoclastogenesis via the Wnt signaling pathway that regulates production of RANKL 
and OPG in osteoblasts [3]. The dense bone mass in Paget’s disease is due to accelerated 
bone remodeling in which bone formation compensates for increased resorption from 
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hypersensitive osteoclasts [40]. Even though bone mineral and matrix are dense in these 
disease states, bone fragility increases since the disorganized accumulation of bone will 
lead to decreased mechanical strength and structural integrity.  
Osteogenesis imperfecta is another genetic bone disease affecting the 
differentiation of mesenchymal stem cells into osteoblasts to produce collagen Type I, an 
important matrix component of bone that provides tensile strength. Patients with 
osteogenesis imperfecta have bone fragility leading to multiple fractures, skeletal 
development retardation, and skeletal deformities. This disease can affect all age and 
gender groups and currently no cure is available. Bisphosphonates are the only known 
broad-spectrum treatment for mild cases; however, in severe cases, especially in children, 
bone marrow transplants are common [41]. Adults with osteogenesis imperfecta can also 
have osteoporosis and threefold higher risk of fractures [42].  
Metastatic bone disease occurs in cancer patients; breast and prostate cancer 
patients have the highest risk, due to radiation chemotherapy and hormonal therapy [43]. 
For example, breast cancer cells express runt-mediated transcription factor 2 (Runx2), 
which is also a master transcription factor for osteoblast differentiation. Runx2 promotes 
the osteoblast lineage in the differentiation of mesenchymal stem cells into immature, 
then mature, osteoblasts. Consequently, mutations of Runx2 are associated with bone 
cancer (osteosarcoma), with undefined pathological mechanisms afflicting children and 
young adults, especially during growth spurts [44, 45]. Management of metastatic bone 
disease and osteosarcoma involves chemotherapy and bisphosphonate therapy to inhibit 
the growth of cancerous bone cells [45, 46]. 
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The pathological environment of bone diseases alters not only bone cell activity 
but also morphology and concentration of osteoblastic and osteoclastic cells. In 
examining the limited histomorphometric studies, the range of precursor bone cell ratios 
for physiological and bone diseases was determined (Table 1.2)[47-50]. The table lists 
number of osteoclasts and osteoblasts per millimeter of bone perimeter, following the 
standard of histomorphometry from the American Society for Bone and Mineral 
Research. From the number of osteoclasts and osteoblasts per bone surface, the cell ratio 
was calculated. The ratios indicate a range of variability in the disease state, a key finding 
for simulating pathological bone environment in co-culture. Furthermore, histology 
shows morphology differences, as compared with normal cells, in osteoclasts and 
osteoblasts involved in Paget’s disease. Advances in understanding the cellular etiology 
Table 1.2. Bone Cell Number via Histomorphometric Analysis of Bone Biopsy 
 Osteoclast (OC) Osteoblast (OB) OC:OB Location Reference 
Control 0.26±0.15mm-1 4.03 ± 1.30 mm-1 1:15.5 Vertebra Pestka. Eur Spine, 2012. 




Control 0.35±0.18mm-1 - - Iliac crest Rauch. Bone, 2000. 
Control 0.30±1.68mm-1 - - Iliac crest 
Rauch. J of Bone 
and Mineral Res, 
2000. 
Paget’s Disease 0.92±0.33mm-1 21.27±10.51mm
-












-1 - - Iliac crest Rauch. Bone, 2000. 
Osteoporosis 0.20±2.04mm-1 - - Iliac crest 
Rauch. J of Bone 
and Mineral Res, 
2000. 
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of common and rare bone diseases will demonstrate the morphological abnormalities and 
concentration differences of osteoblastic and osteoclastic cells.  
For patients with bone diseases, the inherent increased risk of bone fractures is 
dramatic, including increased complications in fracture healing and management. These 
patients must take a high number of precautions during everyday activities and avoid the 
fundamental causes of fracture. 
1.1.4 Causes of Fractures 
Patients suffering from bone diseases are more likely to incur a bone fracture due 
to the compromised mechanical properties of their bones. When bone experiences tensile 
or compressive stresses (cyclic or direct) that exceed the limits of normal bone strength, it 
will fracture. Bones that fracture under normal physiological stress and loading are 
diseased bones with reduced mechanical and physicochemical properties. The anisotropic 
mechanical strength of bone (high longitudinal strength, low latitudinal strength) means 
that bone will most likely fracture into multiple fragments under extreme perpendicular 
and rotational stresses. Fractures can have different levels of severity, from a minor 
micro-crack that goes unnoticed to a major open fracture with a break in the skin and 
damage to the surrounding tissues or organs. Fracture types or patterns are classified as 
[5]: 
• Complete or incomplete 
• Displaced or undisplaced 
• Simple or comminuted 
• Open or closed 
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Each classification has subcategories so that all details of the fracture are 
accounted in order to choose the most effective treatment and management solutions. 
However, an important indicator for intervention options is the patient. Physicians must 
consider the patient age, health condition, type of trauma, site of fracture, bone type, and 
fracture type.  
In the case of osteoporotic fractures, prevalence of fractures in the spine and 
proximal femur are higher in older patients as compared to younger patients, with high 
risk for distal radial fractures. Vertebral fractures in osteoporotic patients occur under 
normal body weight and will cause deformities of the spine and chronic back pain. 
Management of spinal fractures includes use of bone grafts and fixation devices for 
spinal fusion to redistribute load, while femoral fractures are immobilized by 
intramedullary nails or plates to induce bone healing.  
Since bone fractures are more prevalent in patients with bone diseases, 
pharmacological treatments targeting specific remodeling processes will suppress healing 
reactions at the fracture site. This suppression will lead to high rates of non-unions for 
this category of patients [30, 51]. The juxtaposition of inhibitory protective agents and 
fracture healing has little consideration in the management of bone fractures and the 
development of substitute bone. Hence it is important to review the advances and gaps 
with respect to implementation of pharmaceutical agents and bone substitute materials for 
fracture healing in diseased bone. 
1.4 Review of Advances in Bone Tissue Engineering and Regenerative Medicine 
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1.1.5 Clinical Approaches to Bone Diseases and Defects 
Expanding knowledge of bone abnormalities has enabled innovative diagnosis 
capabilities, surgical procedures, and therapeutic solutions. Clinical approaches focus on 
bone protective therapy for the aging population and cancer patients with osteoporosis 
and bone metastases, respectively. The majority of therapeutic medicines for bone 
diseases disrupt the osteoclastic (anti-resorptive/anti-catabolic) pathway and promote the 
osteoblastic (pro-anabolic) pathway [3]. Fracture management surgical interventions for 
diseased bones are limited to solutions designed for healthy bone with normal bone cell 
activity.  
Pharmacological therapies targeting abnormal cell signaling in benign and 
malignant bone diseases can provide effective solutions but have complicated side effects 
[52, 53]. For example, bisphosphonates are a broad spectrum class of drugs used for 
many osteoporotic types to inhibit resorptive activities; however, the side effects can 
include renal dysfunction, gastrointestinal complications, or even osteonecrosis of the jaw 
[3, 46, 54]. Other studies have revealed the benefits of bisphosphonates, which have 
apparent anti-tumor effects when administered to cancer patients suffering from 
osteolysis or which, in combination with chemotherapy, inhibit the growth of 
osteosarcoma cells [45, 53]. Bisphosphonates are also administered to osteoporotic 
patients with total hip replacements to prevent aseptic loosening and peri-implant 
osteolysis [55]. Denosumad is an anti-resorptive pharmaceutical agent targeting RANKL 
signaling in osteoclast activation; a clinical study showed the agent’s anti-fracture 
efficacy for women with postmenopausal osteoporosis, i.e. reduced fracture incidence in 
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vertebrae and increased bone mineral density in the hip [3]. Other bone-modulating 
agents target the protolytic enzyme cathepsin K, the Wnt pathway (indirect RANKL and 
OPG regulation), and calcium-sensing receptors to downregulate hormonal stimulators 
(parathyroid hormone) in bone remodeling [3, 25]. These agents are only medicinal 
therapies that prevent disease exacerbation; they do not prevent bone fragility and risk for 
painful fractures.   
Surgical intervention is used to stabilize fractures in healthy bone with internal 
fixation devices and bone substitutes, providing a mechanically favorable environment 
and template for bone healing. For fractures in long bones, like the femur and humorous, 
implanted fixation devices provide rigid stability using screws and plates; bone 
substitutes are sometimes used to bridge the fracture gap. The traditional screws and 
plates are also used for the fixation of osteoporotic fractures in which the stability of the 
device depends on the integration of the screw to the bone. However, the stability of the 
traditional fixation system is compromised by the low bone mass in osteoporotic bone. 
Consequently, implant loosening and progressive instability will cause nonunions at the 
fracture gap [56]. Proximal femoral fractures in older patients are treated with urgent 
attention to control of bleeding and to achieve successful fixation and minimize future 
complications. In bone metastatic diseases, surgical intervention is intended to control 
tumor growth and provide load-bearing capabilities to the defective area [57]. Insufficient 
recognition of compromised bone mechanics in diseased bone has lead to implant failures 
and increasing patient suffering [58]. However, efforts towards redesigning the screw and 
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plate systems for low quality bone have been ongoing with products such as angular 
stability screws and plates, and bicortical screws [56, 58, 59].  
Fracture management also depends on the enhancement of fracture healing with 
autografts and allografts. The practice of graft implantation has grown in the past two 
decades, as indicated by the $300 million market in 1999, to an astounding $1.6 billion in 
2008 as estimated by the Orthopedic Network News [60]. Bone grafting procedures are 
predominantly performed in the spine (80%), with combinations of bone morphogenic 
protein to encourage regenerative bone fusion. The incorporation of BMP was one of the 
first approaches to bone tissue engineering; many advances have been achieved to 
enhance bone healing and formation, with some focus in bone diseases. 
1.1.6 Bioactive and Regenerative Advances 
The transition into regenerative practices is evident in the rise of bone substitute 
purchases of 28.6% in 2006 to 51.6% in 2007, in conjunction with the ~12% increase in 
BMP purchases [60]. The shift in focus is an effort to explore promising pathways of a 
functional bone substitute via cellular factors, chemical factors, and molecular factors to 
stimulate bone regeneration, even in abnormal bone conditions. The use of autologous 
bone marrow and its cellular components with bone substitutes is an emerging alternative 
to enhance osteogenicity and osteoconductivity [61]. Bone substitutes can also be carriers 
for disease-targeting macromolecules in the anti-catabolic and pro-anabolic pathways for 
local delivery [62]. Other strategies combine the effects of systemic bone protective 
agents with local delivery of molecular osteogenic factors [63]. Innovative development 
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of functionalized substitute bone has the capacity to resolve the rising demand for bone 
tissue transplantation in the aging population due to the rise in bone diseases. 
The bone substitute construct or scaffold serves as a temporary template for 
cellular recruitment, differentiation, and matrix deposition in bone regeneration and 
provides continuity in mechanical stability at the defective area. The strategy of using 
functionalized bone scaffolds focuses on stimulating and directing all four phases in the 
bone healing reaction. The functionality depends mainly on the biomaterial of choice and 
the retention of potency and efficacy of the supplements within the defect bone.  
Fabricating a sophisticated biomaterial that can mimic the innate regenerative 
capacity of bone tissue is a challenge. Strategies incorporating biomimetic bone scaffolds 
have focused on the use of bone marrow and platelet rich plasma to enhance 
osteoinductive properties of substitute bone grafts in an intraoperative procedure [61]. 
Researchers have infused anti-anabolic and pro-catabolic agents and molecular factors to 
stimulate bone cell activity in various bone scaffolds [64].  
Cellular Factors: Bone Marrow 
Bone marrow is a source for osteoprogenitor and hematopoietic stems cells; 
therefore, cellular grafting of autologous marrow aspirate is of high interest for enhancing 
fracture unions [63, 65]. Bone marrow has been used in its entirety and in fractions, 
depending on the bone defect. Various methods of bone marrow extraction have been 
evaluated to isolate marrow stromal cells, mesenchymal cells, hematopoietic stem cells, 
and even marrow fat cells [61, 66]. Whole bone marrow transplants are commonly 
performed for genetic bone diseases such as osteopetrosis and osteogenesis imperfecta in 
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order to replace abnormal bone cells with normal cells. As for alveolar bone defects in 
the maxilla, allografts are pre-soaked in bone marrow before implantation to mediate 
enhanced bone healing [67, 68]. In long bone fractures, intramedullary nails are 
implanted into the canal of the long bone to provide rigid stability for enhanced union. 
The implantation of the intramedullary nail requires the surgeon to ream the bone canal, 
which generates reamed aspirate that is filtered and divided into intraoperative 
autologous osseous particle and filtrate waste. The osseous aspirate material containing 
bone fragments is placed onto the defect to enhance osteoconductivity of the allograft or 
bone substitute bridging the fracture gap [69, 70].  
However, the waste filtrate or the liquid flow-through from the reaming process is 
of high interest for its osteogenic potential with cellular components and various growth 
factors involved in bone metabolism [65]. Porter and coworkers confirmed that the 
filtrate had growth factors such as PDGF, VEGF, and TGF, along with multipotent cells 
expressing an MSC phenotype [65, 71]. This conservative approach to re-incorporate the 
filtrate will further enhance the osteoinductive environment of the allograft and bone 
scaffold. 
Current intraoperative enhancements of allografts and commercially available 
bone substitutes using whole bone marrow can have complications. The recent discovery 
that adipocytes found in bone marrow regulate osteoblast bone formation and osteoclast 
bone resorption through fatty acid and hormonal secretions may explain the prevalence of 
osteoporosis in geriatric patients since marrow fat increases as bone ages [35]. The use of 
bone marrow cellular components refined for optimal bone formation and resorption can 
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be of benefit. However, bone marrow and its components are limited in quality, and even 
quantity, depending on the patient and the marrow extraction procedure [70]. 
Chemical Factors: Protective Biomolecules 
An alternate treatment should be chosen for patients with bone diseases, who are 
incompatible for marrow transplants since the abnormal potential of autologous marrow 
stem cells could result in non-union healing. In these instances, strategies of 
incorporating and loading bone-protective agents within the bone substitute for local 
delivery are more advantageous [62, 72, 73]. Current understanding of the exact 
mechanism, release rate, degradation, and dosage of the biomolecule in the scaffold is 
limited, and future work should include in vitro or in vivo simulations to understand the 




















Figure 1.3. Bone protective agents targeting specific osteoblast anabolic and osteoclast catabolic 
activities to improve bone quality and prevent disease acceleration. Adapted from [3]. 
 32 
Table 1.3. Bone Protective Agents 
Name Activity 
BHQ-880 Inhibits dickkopf-1 from interfering with Wnt signaling to promote bone formation 
AMG-765 Inhibits sclerostin from interfering with Wnt signaling to promote bone formation 
Denosumab Inhibits RANKL and RANK signaling to prevent osteoclast activation 
Bisphosphonate Inhibits Rho and Rab signaling for osteoclast survival and activity 
Odanacatib Inhibits cathepsin K (Cap K) production of degradation lysozyme  
 
Pharmacological agents used to treat bone diseases target specific signaling 
pathways within bone cell differentiation and activity (Figure 1.3 and Table 1.3). These 
biomolecules act to neutralize the inactivity of osteoblasts and hyperactivity of 
osteoclasts commonly found in osteoporosis for a more effective and accurate induction 
or inhibition, with limited side effects. Bisphosphonates are currently the most widely 
used protective agents, due to their approved status for treating osteoporosis, the most 
common bone disease. Consequently, strategies for loading protective biomolecules 
concentrate on incorporation of bisphosphonates, mainly in soluble calcium phosphate-
based scaffolds and bone cement [73, 75, 76]. Faucheux and coworkers demonstrated that 
zoledronate, a potent bisphosphonate, loaded on calcium phosphate inhibited osteoclast 
activity without affecting osteoblast activity [77]. With local inhibition of osteoclast 
activity, investigators speculate that the initial application of the drug encourages bone 
formation within the bone scaffold, then allows osteoclast resorption to remodel the bone 
scaffold and woven bone. Further development is still needed to determine the precise 
release kinetics, loading efficacy, and distribution zone, while conserving the integrity of 
the bisphosphonates for an optimal bioactive scaffold. As more anti-catabolic and pro-
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anabolic pharmaceutical treatments become available, strategies for different local drug 
delivery systems will evolve to allow the development of functional bone scaffolds 
specific to various bone diseases.  
Molecular Factors: Cytokines, Steroids, and Growth Factors 
A more direct approach is to deliver the molecules orchestrating bone resorption 
and formation reactions with the bone scaffolds. Some investigators have loaded 
cytokines, steroids, and growth factors to emphasize anabolic or catabolic activity during 
the phases of bone healing. To initiate phase 1 of the bone healing reactions, platelet-rich 
plasma, a source for platelet-derived growth factor and transforming growth factor, has 
demonstrated its ability to activate inflammation and coagulation for recruitment of 
progenitor and stem cells [63, 78, 79]. Since the discovery of recombinant human BMP-2 
and BMP-7 to promote osteoblast differentiation, the use of allografts loaded with BMP 
has increased for spinal fusion and tibial fracture repair. Li and coworkers developed a 
method to load BMP-2, using gelatin microspheres, into macroporous calcium phosphate 
cement for controlled release with enhanced osteoinductivity [80]. The efficacy of BMP 
in long bone fractures is still under investigation; hence, there is an ongoing search for 
alternate proteins to stimulate good bone healing reactions. Miller and coworkers have 
investigated an intraoperative approach to incorporate dexamethasone, a synthetic steroid 
stimulating differentiation of MSCs into osteoblasts, with bone aspirate to mediate 
reclaimed progenitor cells towards osteoblastic commitment [81]. Another approach by 
Arrighi and coworkers was to immobilize active fragments of parathyroid hormone 
(PTH) on fibrin matrices for local delivery, to increase bone turnover without systemic 
 34 
side effects [82]. Parathyroid hormone treatments have been used for osteoporosis 
treatment to maintain calcium homeostasis in bone for indirect regulation of bone 
turnover; however, PTH is a broad-spectrum mediator of other metabolic activities in 
which a systematic exposure would produce additional complications [63].  
With increased sophistication of bioactive scaffolds, design challenges and 
constraints will increase. Variability of the bone substitute will increase due to the 
incorporation of cellular, chemical, and molecular factors. Preservation and retention of 
bioactive structure and potency can be insufficient due to material processing and 
scaffold construction. Consequently, with limited pharmaceutical agents approved for 
clinical use, a collaborative effort from bone tissue engineering, regenerative medicine, 
and pharmaceutical sciences is necessary to investigate synergistic approaches for a 
bioactive bone substitute scaffold for treatment of fragility fractures in patients with bone 
diseases. 
1.1.7 Bone Substitute Biomaterials and Constructs 
The basis for a sophisticated bone scaffold is the biomaterial that embodies the 
mechanical and physiological properties of the scaffold. Substitute bone constructs must 
provide skeletal continuity with mechanical integrity to transmit load, biological 
compatibility to avoid immune response, nontoxic degradation to allow new bone 
replacement, and mediators to encourage bone healing, even in unfavorable environments 
of diseased bone. Materials of choice include ceramics, natural polymers, synthetic 
polymers, and their composites. Bone tissue engineers will use biomaterials to engineer 
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bone substitute constructs that can mimic aspects of native bone to bridge the fracture gap 
as a temporary 3D template with regeneration potential.  
Ceramics are the most commonly used materials in bone fracture repair because 
of their compressive strength and abundant supply; additionally, the solubility of calcium 
phosphate and hydroxyapatite compliments that of common bone protective agents. 
Commercially-available bone substitutes, listed in Table 1.4, are mainly based on 
ceramics, leveraging their osteoconductive nature, nontoxic degradability, compressive 
strength and long shelf-life. While variability for clinically-approved materials is limited, 
calcium phosphates, calcium sulfates, and hydroxyapatite materials are versatile, soluble 
materials that can be combined with ductile polymers and carry mediators. Currently, the 
clinically available products are essentially serving as bone fillers; however, transition of 
the clinically-approved bone substitutes into bioactive or functional substitute bone 
would be easier and quicker than developing novel biomaterials for treating fragility 
fractures in diseased bone. 
Table 1.4. Commercially-Available Bone Substitutes 
Company Product Material 
Biomet Spine Pro-Osteon Hydroxyapatite over a calcium carbonate core 
Orthovita Vitoss β-Tri-calcium phosphate (β-TCP) 
Smith & Nephew Jax Bone Void Calcium sulfate 
Sofamor Danek MasterGraft Mix β-TCP and hydroxyapatite 
Stryker HydroSet HA Bone Calstrux 
Calcium phosphate cement 
β-TCP granules and carboxymethylcellulose 
Synthes chronOS β-TCP granules 
Wright Medical 
Group 




Proprietary alpha crystal technology 
Triphasic calcium salt 
Zimmer CopiOs Calcium phosphate 
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Table 1.5. Examples of 3D Bone Substitute Construct Designs 
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βTCP = β-tricalcium phosphate, αTCP = α -tricalcium phosphate PL = polylactide, PLG = poly(lactide-co-
glycolide), HA = hydroxyapatite, BCP = biphasic calcium phosphate 
Polymers, on the other hand, are comparatively more versatile than ceramics in 
processing, manufacturing, and manipulation, including rapid prototyping, 
electrospinning, and in situ hardening of nanofibers, macroporous sponges, and 
microspheres (Table 1.5). Natural polymers like chitosan, collagen, and hyaluronic acid 
have inherent physicochemical and mechanical properties that can be adjusted through 
processing for an intended use [83]. For example, chitosan derived from the exoskeleton 
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of crustaceans has intrinsic antibacterial properties, biologically reactive functional 
groups, nontoxic degradation, and ductility [83, 84]. There also exist synthetic polymers 
such as polylactide (PL), polyglycolide (PG), polyanhydride, and their copolymers that 
can be fabricated into varying 3D matrix shapes with sufficient mechanical strength and 
controlled degradation [83, 85]. However, the foreign body response to degradation by-
products of orthopedic implants made from synthetic polymers such as polyglycolide and  
PL orthopedic implants is non-ideal [86]. To minimize PL or PG bulk mass loss, 
scaffolds are fabricated with composite materials incorporating ceramics and polymers. 
Composites such as chitosan/calcium phosphate and poly(lactide-co-glycolide) 
(PLG)/hydroxyapatite (HA) have been manipulated to mimic bone architecture and 
increase biocompatibility [87].  
Once a biomaterial or a composite of biomaterials is chosen, the challenge is to 
engineer substitute constructs conforming to an array of criteria – architectural 
organization, biocompatibility, osteoinductivity, osteoconductivity, biomechanics, 
biodegradability, and, most recently, bioactivity – to become biomimetic and functional 
as autologous bone. The 3D architectural organization of the material may have 
interconnected pores to allow host cell migration, nutrient and waste diffusion, and blood 
capillary formation. However, finding a synthetic material with high porosity and 
mechanical integrity proves to be a challenging proposition. In addition to overall 
architecture, surface micro-topography or roughness can enhance cell attachment and 
protein adsorption in bone regeneration. A biomaterial scaffold should be relatively 
biocompatible, eliciting no immune response while encouraging cell attachment and 
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proliferation. The scaffold matrix should provide an osteoconductive and osteoinductive 
environment to recruit progenitor cell attachment, then support and stimulate 
differentiation of active bone cells for fracture healing. The scaffold should be absorbed 
or remodeled by bone cells and absorbed, remodeling/absorbing at a rate at which 
biomechanical stability is sustained and cellular responses stimulated as load is 
transmitted.  
To advance regenerative medicine, bone substitute constructs have become 
biomimetic, bioactive, and functional, serving as drug delivery systems [88]. Current 
investigations are focused on mechanisms of loading and solubilizing a biomolecule into 
the material itself before scaffold construction, or adsorbing and absorbing the 
biomolecule into the scaffold after production. Novel approaches use calcium phosphate 
as a drug carrier in electrospun polymers or injectable bone substitutes [55, 74, 76].  
In vitro and in vivo assessments are essential to evaluate scaffold properties and 
potentials in encapsulating and eluting drugs in a controlled manner to target the 
pathology of the particular bone disease. As a review by Baroli suggested, 
pharmaceutical scientists focused on bone regeneration will face the challenge of 
choosing a specified agent for one particular mechanism in spite of the reality of a 
multitude of pathways that orchestrate bone healing reactions [62]. An in vitro test 
system can simulate a specific abnormal pathway in the bone disease and allow 
consistent characterization of the molecular agent of interest along with fundamental 
understanding of the bone substitutes in the pathological conditions. Each molecular 
factor, cytokine, and hormone supplement in cell culture medium has been extensively 
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studied to obtain the optimal concentration and ratio; however, the effects of cell 
concentration and ratio with respect to each other have been of little interest. 
Furthermore, the determination of the influence of adipocytes in bone cell regulation has 
received inadequate consideration. Some bone diseases are due to the imbalance of cell 
ratios and cellular signaling, which can lead to hyperactivity of one and hypoactivity of 
the other, resulting in bone malignancies. To simulate in vivo conditions effectively, a 
standardized multicellular system should be established to incorporate key cell types, 
comparable cell ratios, and molecular controls to allow a coordinated stimulatory 
environment for all cell types within an in vitro culture. A multicellular system will allow 
efficient characterization and evaluation of the bone scaffold before advancing into in 
vivo and clinical testing. 
For example, in a case study presented by Eder and coworkers chronOS produced 
by Synthes was explanted 28 months after a spinal fusion of a 41 year old female patient 
with scoliosis [89]. The explant showed no sign of material resorption and no sign of 
bone cell attachment or proliferation. The manufacturer claimed complete resorption of 
the β-tri-calcium phosphate within 6-18 months, which was most likely estimated 
with no consideration of pathological bone metabolism [89]. With an in vitro 
system that can characterize the synthetic material under pathological conditions, 
an expedited preliminary screening can estimate potential disadvantages of the 
material. 
The evolution of bone tissue engineering must include high consideration for 
overall patient physiology as well as the objective of fracture management. The process 
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of translating scaffold innovations into clinical applications will involve extensive in 
vitro and in vivo evaluations to ensure all essential criteria are incorporated – 
biodegradability, compressive strength, bioactivity, 3D architecture, manufacturing, 
handling, etc. By implementing more requirements for developing functional scaffolds, 
investigators will face more constraints in their challenging endeavor for an ideal 
regenerative bone substitute.  
1.1.8 Constraints in Bone Tissue Engineering 
The design of a drug-delivering scaffold to serve as a template for bone formation 
and structural support, with the ability to elute biomolecules to mediate normal bone 
healing reactions in an abnormal environment, is a challenging endeavor. Systemic 
delivery of protective bone agents inhibits bone cell malfunctions and interferes with the 
bone’s capacity to repair, while local delivery of growth factors and cytokines stimulates 
bone cell remodeling activities at the fracture site. An ideal bone substitute scaffold 
would have controlled and sustained drug release, would conserve drug potency and 
efficacy, would be low cost, and have a long shelf-life. The encapsulation techniques 
should allow predictable control of a biomolecule concentration and of the elution 
profile; however, potency and efficacy can be limited by the degradation profile of the 
material and the stability of the molecule immobilized in the scaffold. During the 
incorporation of the drug into the scaffold, minimal or no conformational changes to the 
molecular structure should occur to avoid alterations to drug activity and potency [89].  
The production cost of a scaffold should be minimal, allowing ample supply with 
no loss in scaffold functionality. The addition of the biomolecule is the limiting factor 
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constraining the advances in bioactive scaffolds, especially when dealing with molecular 
factors of purified proteins, cytokines, and growth factors. Constraints in potency and 
efficacy can be a comparable tradeoff for quantity and quality limitations of autografts 
and allografts. Tunability in construct organization and physiochemical properties will 
allow specialized substitute scaffolds for different abnormal physiological environments.  
1.5 Summary 
As commonly taught in biology classes, function follows form; however, in the 
case of the body, function follows physiology. Therefore, the fracture management 
strategies in pharmaceutical therapy, surgical intervention, and tissue regeneration should 
follow the patient’s bone physiology. Patients with bone diseases undergo protective 
bone treatments to prevent fragility fractures by inhibiting abnormal cell activity, not by 
restoring normal activity. However, when a pathological fracture is sustained, surgical 
interventions tend to implement traditional methods of stabilization and fail to account 
for compromised bone mechanics. Regenerative bone grafts are commonly used to 
provide skeletal continuity for critical size fractures; however, the regenerative capacity 
of the graft can be hindered by the protective bone agent. Consequently, it is essential to 
integrate all three management strategies to establish a well-rounded treatment that can 
mediate bone healing in a diseased bone environment.  
Engineering approaches are evolving toward treatment of high risk fragility 
fractures in pathological bone with low quality bone fixations and functionalized bone 
scaffolds. Hence, function will follow pathology as increased understanding of bone 
diseases is applied towards designing disease-specific systemic and local bone 
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treatments. Incorporation of bioactive factors should be the norm in the advancement of 
engineered fixation devices and bone scaffolds. However, much research is needed to 
determine optimal methods and procedures to load and encapsulate the factors without 
compromising efficacy. By focusing on regenerative responses in the pathological bone 
environments, bone tissue engineering will be able to target the specific abnormality of 
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CHAPTER TWO  
A CO-CULTURE CHARACTERIZATION OF PRECURSOR CELL RATIO FOR 
OSTEOCLAST AND OSTEOBLAST DIFFERENTIATION 
2.1 Introduction  
Bone is a complex and dynamic tissue with physiological properties and three-
dimensional (3D) organization to maintain bone health and functionality. Bone cells are 
constantly communicating with each other to instantaneously respond to physical, 
biological, and endocrine stimuli. A signaling cascade causes coordinated cell activity, 
leading to renewal and/or repair depending on the specific internal and external mediators 
[1-3]. Upon damage due to traumatic injuries or mechanical stress exceeding 
physiological healing conditions, therapeutic intervention is required to facilitate good 
bone union. Common therapeutic practices are rigid fixation and bone graft implantation, 
which provide a mechanically and biologically favorable environment for healing [4-6]. 
Current clinically available bone grafts are autografts and allografts, i.e. bone tissue 
retrieved from the patient or retrieved from donor tissue, respectively [7].  
Within the United States, the ≥65 population of baby boomers will exceed 77 
million in 2020; this population has the highest prevalence for osteoporosis and fractures 
due to low bone mass. Consequently, the demand for bone graft implantation will exceed 
the allograft supply, and autograft retrieval can be complicated for older patients [8, 9]. 
Low biological activity and regenerative capacity of allografts and autografts necessitate 
alternate therapeutic options [10-12]. Therefore, bone tissue engineering strategies are 
sought to develop bone substitute materials that can induce bone healing with their 
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inherent chemical, biological, and mechanical properties [5, 6]. However, ceramic, 
polymeric, and composite materials have limited strength, architecture, degradability, and 
biocompatibility, as compared to native healthy bone, with respect to facilitating the 
healing cascade [11]. Current investigations focus on material enhancements using 
regenerative medicine principles of incorporating isolated cells, chemical factors, and 
growth factors via adsorption and absorption.  
Bone substitute materials bioactivity is limited to mediating bone regeneration 
within in the normal bone environment and does not address compromised healing 
reactions of diseased bone which is susceptible to non-unions. Advancements in bone 
tissue engineering and regenerative medicine must address cellular and metabolic 
abnormalities of bone diseases to effectively treat fragility fractures. In order to 
characterize the bioactivity of substitute designs, in vitro and in vivo testing systems must 
simulate normal and diseased bone physiology. 
Transgenic animals have advanced the understanding of the dynamic complexity 
of native bone cell coordination and of the differentiation into the osteoclast and 
osteoblast lineages [13, 14]. However, in vitro simulation of bone pathology is lacking, 
due to the complexities and inconsistencies in current co-culture systems that attempt to 
highlight osteoclastic and osteoblastic metabolic coupling. The coordination is 
exemplified in the intertwined signaling pathways of hematopoietic and mesenchymal 
stem cell differentiation along the osteoclastic and osteoblastic lineage. Secreted 
cytokines and factors from either lineage can mediate maturation and activity of the other 
[15, 16]. For example, receptor activator of nuclear factor kappa-B ligand (RANK ligand) 
  
 51 
is the key factor produced by osteoblasts to signal osteoclast differentiation through the 
RANK pathway, leading to activation of transcription factors [17, 18].  
The coordinated partnership is also evident in the bone remodeling cascade, with 
a balance in bone resorption and deposition needed to maintain bone health at a defined 
ratio of cell concentration and mediators [14, 19]. Any deviation from homeostatic bone 
remodeling and balance in cell ratio can result in bone diseases like osteoporosis and 
osteopetrosis [20-22]. Histomorphometric evidence of bone biopsies of healthy and 
diseased bone exemplifies the morphology and cell ratio differences of osteoclast and 
osteoblast cells. For Paget’s disease and bone metastasis from breast carcinoma, the cell 
ratios of osteoclast to osteoblast were calculated to be 1:23.1 and 1:1.6, respectively, 
while healthy biopsies exhibit a ratio of 1:15 [23, 24]. Consequently, a co-culture 
approach to evaluate bone cell response to bone substitute bioactivity is necessary, and 
understanding the consistency and relevancy of culture parameters to native bone 
metabolism is essential.  
The objective of this study was to determine the effect of specific culture 
parameters, i.e. precursor cell ratio and differentiation supplement mediator (soluble 
RANK ligand), on osteoclast and osteoblast differentiation. Co-culture was conducted, 
with three different cell ratios of RAW monocytes and D1 stromal cells under osteogenic 
conditions, to monitor differences in lineage maturation. This study also focused on 
hematopoietic differentiation in osteogenic and RANK ligand-supplemented conditions 
to examine the necessity of the additive in co-culture conditions, where RANK ligand is 
secreted by osteoblasts. Gene expression levels of early and late bone cell maturation 
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markers were quantified to monitor if in vitro cellular differentiation and activation was 
characteristic of that of native bone cells. 
2.2 Methods 
2.2.1 chronOS Granule Sterilization 
To simulate the in vivo environment of bone, chronOS (Synthes) β-tricalcium 
phosphate cancellous bone substitute was used as the three-dimensional (3D) matrix for 
cell co-culture. The 150mg of granules were placed in scintillation vials (Wheaton) 
without caps and sterilized at 200°C under 10 psi, in a vacuum oven (VWR Symphony) 
for at least 2 hours. The vials were immediately transferred from the oven to the 
Steriguard biological cabinet to be capped with autoclaved vial tops.  
Table 2.1. Experimental Setup (n=3) 
Cell Ratio (RAW:D1) Osteogenic (OS) Medium 
Osteogenic Medium with 
RANK ligand (R) 
1:1= 76000 RAW : 76000 D1 OS1 R1 
1:10 = 7600 RAW : 76000 D1 OS2 R2 
1:100 = 760 RAW : 76000 D1 OS3 R3 
Fluorescence Imaging Samples: OS1, OS2, R1, R2 
Controls: growth medium with 1:100 ratio on ChronOS 
 
2.2.2 Cell Culture 
Murine RAW 294.7 monocytes (ATTC) and D1 stromal cells (ATCC) were 
seeded on chronOS granules in 24-well plates (Corning) with osteogenic medium 
(Dulbecco’s Modified Eagle’s Medium (DMEM) (Atlanta Biologics) supplemented with 
10% fetal bovine serum (Gibco), 1% penicillin/streptomycin (ATCC), 0.2% fungizone 
(Invitrogen), 0.1µM dexamethasone (Sigma), 10mM β-glycerophosphate (Sigma), 
  
 53 
5µg/ml ascorbic acid (Sigma)) supplemented with 30ng/ml RANK ligand (Pepro Tech) 
or no supplement. The D1 cells were co-cultured with RAW 294.7 monocytes and 
stimulated to differentiate into osteoblasts and osteoclasts, respectively. Each well plate 
contained 150mg of chronOS granules; the granules were presoaked in growth medium 
for 24 hours at 37°C prior to cell seeding. The experimental layout for the co-culture of 
RAW to D1 cell density ratios and experimental groups are shown in Table 2.1. The 
culture was maintained for 36 days, samples were collected at Days 8, 15, 22, 29 and 36, 
and the medium was changed every other day. 
2.2.3 Fluorescence Imaging 
Endogenous phosphatases, suggestive of bone cell differentiation, such as 
osteoclast characteristic tartrate-resistant acidic phosphatase (TRAP) granules and 
osteoblast alkaline phosphatase (ALP) were visualized using fluorescence-based ELF97 
staining (ELF97 Endogenous Phosphatase Detection Kit, Molecular Probes). Additional 
samples (experimental groups: OS1, OS2, R1, R2) were cultured on four-well chamber 
slides (Lab Tek II) for better image quality (Table 2.1). ELF97 staining was performed at 
endpoint Day 36 following the manufacturer’s protocol, with two counterstains to reveal 
a more defined cellular morphology. Hoechst 33342 (Invitrogen) was used to stain cell 
nuclei blue while AlexaFluor 546 Phalloidin (Invitrogen) was used to stain cytoskeleton 
actin red, to contrast with the green fluorescence of ELF97. Images were taken using the 
microscope (Axiovert 40 CFL, Zeiss) with attached fluorescence lamp under 
Hoechst/DAPI and TRITC filter sets.  
Ribonucleic Acid (RNA) Isolation 
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To analyze gene expression of differentiation markers of cells attached to the 
granules, total RNA was isolated at Days 8, 15, 22, 29, and 36 using the TRIzol reagent 
(Invitrogen) and protocol. Briefly, medium was removed from well plates before 1 ml 
TRIzol reagent was added to lyse cells, then 0.2 ml of chloroform (Honeywell, HPLC 
Grade) was added to dissolve RNA into an aqueous phase. The RNA was collected, 
precipitated with 0.5 ml isopropyl alcohol (VWR), and washed with 1 ml 75% ethanol 
(Sigma). The ethanol was removed and the precipitated RNA was air dried before 
resuspending in 30µl of nuclease-free water (Promega). Next, the RNA was treated to 
remove any contaminant DNA, using the TURBO DNase-Free kit (Ambion). RNA was 
quantified and qualified using a NanoDrop 1000 spectophotometer (Thermo Scientific), 
then stored at -80°C until reverse transcription. 
2.2.4 Reverse Transcription Real-Time Polymerase Chain Reaction (RT-PCR) 
Reverse transcription was performed using the RETROscript kit (Ambion) with 
1µg of isolated RNA to synthesize 25 ng/µl of complementary deoxyribonucleic acid 
(cDNA). QuantiTect SYBR Green kit (Qiagen) was used to perform real-time PCR with 
the primers listed in Table 2.2. Primers were checked for uniqueness with Primer-BLAST 
database and efficiency prior to purchase and use, respectively. The StepOne Plus 
(Applied Biosytems) was used to run PCR at a holding temperature of 95°C for 15 min, 
then 35 cycles of denaturing at 94°C for 15 sec, annealing at 54°C for 20 sec, and 
extension at 72°C for 20 sec. Melting occurred at a 70-99°C ramp to check for primer 
dimers. The cycle number (Ct) was obtained at a threshold of 0.1 to calculate relative 
  
 55 
expression ratios (RER) of target genes compared to the internal standard, GAPDH, using 
the ΔΔCt method as follows: 
  RER = 2(-ΔΔCt) 
  ΔΔCt = ΔCt(experimental) –ΔCt(control) 
  ΔCt(experimental) = Ct(target) – Ct(reference) 
ΔCt(control) = Ct(target) – Ct(reference) 
Table	  2.2.	  RT-­‐PCR	  Primers	  




F	   5’-­‐GAACGGATTTGGCCGTATTG-­‐3’	  	  
[25]	  	   R	   5’-­‐CGTTGAATTTGCCGTGAGTG-­‐3’	  
Osteoblast	  Early	  Differentiation	  Marker	  
	  
Runx2	  
F	   5’-­‐AGTGGACCCTTCCAGACCAG-­‐3’	   	  
	   R	   5’-­‐TAATAGCGTGCTGCCATTCG-­‐3’	   	  
	  
ALP	  
F	   5’-­‐GTAACGGGCCTGGCTACAAG-­‐3’	   	  
	   R	   5’-­‐AAAGACCGCCACGTCTTCTC-­‐3’	   	  
Osteoblast	  Late	  Differentiation	  Marker	  
	  
Osteocalcin	  
F	   5’-­‐TGCGCTCTGTCTCTCTGACC-­‐3’	   	  
	   R	   5’-­‐ATGGAAGGCTAAGGGCTCTG-­‐3’	   	  
	   Osteopontin	   F	   5’-­‐AAAGAGAGCCAGGAGAGTGCC-­‐3’	   	  




F	   5’-­‐GGACGTTCACACTGGTCAGC-­‐3’	   	  
	   R	   5’-­‐TGCTTCCCTGCTGGATTAGG-­‐3’	  	   	  
	  
NFATc1	  
F	   5’-­‐CTCGAAAGACAGCACTGGAGCAT-­‐3’	  	  




F	   5’-­‐CTGCCTTCCAATACGTGCAG-­‐3’	  	   	  
	   R	   5’-­‐CCTTTGCCGTGGCGTTATAC-­‐3’	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2.2.5 Western Blotting 
A different study was conducted following a similar protocol to collect protein 
lysate for protein production quantification. The difference between the two studies was 
the collection time point at Days 7, 14, and 21. Samples were rinsed with phosphate 
buffered saline (PBS) (Sigma) twice, before 150µl of Mammalian Protein Extraction 
Reagent (M-PER) (Pierce) was added. The samples with M-PER were ultrasonicated 
(Sonic Dismembrator, Fisher Scientific) for two 3-second cycles. The lysate was 
collected and centrifuged (X-12R, Allegra) for 5 minutes at 14,000rpm, then stored at -
4°C until the end of the study. Bicinchoninic acid (BCA) protein assay (Pierce, Thermo 
Scientific) was performed to quantify total protein concentration per sample for gel 
electrophoresis. Total protein (40µg) was diluted with Laemmli sample buffer (Bio-Rad) 
and distilled water, for a total volume of 30µl, and loaded onto 10% Tris-HCl Criterion 
gels (Bio-Rad). Proteins on the gel were blotted onto 0.45µm nitrocellulose membranes 
(Bio-Rad) for protein detection. Primary antibodies for osteopontin (66kDa) and Runx2 
(55kDa) (Rabbit-anti-mouse, Santa Cruz), followed by secondary goat-anti-rabbit 
conjugated with horseradish peroxidase (HRP), were used to detect protein at specific 
molecular weights. Beta-actin (42kDa) conjugated with HRP (Cell Signaling) was used 
as the internal standard. Chemiluminescence imaging was performed using FluorChem™ 
M (Protein Simple).  
2.2.6 Statistical Analysis 
The calculated relative expression ratio (RER) average and standard error were 
graphed for each target gene. JMP 10 (SAS) was used to perform all statistical analyses 
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to detect interaction among the cell ratios, in two differentiation conditions, over time. 
Randomized splitplot was implemented to statistically compare gene expression 
differences within medium groups (wholeplot) for each cell ratio (subplot) within days. If 
significance in the interaction was detected (p<0.05), Tukey-HSD post-hoc analysis 
(alpha=0.05) was performed to determine significant effects of the factors. Data averages 
were graphed with standard error of mean.   
2.3 Results  
2.3.1 Endogenous Phosphatase Staining 
Fluorescent ELF97 staining images show that phosphatases are present in cell 
clusters for both medium conditions of osteogenic and osteogenic supplemented with 
Figure 2.1. ELF97 endogenous phosphatase images for Day 36 of the study, 
for OS and R groups at 1:1 and 1:10 ratios. Blue, red and green fluorescence 
indicate nuclei, actin, and phosphatase, respectively. Positive staining for 
phosphatase is seen for all samples. Scale bar indicates 50µm. 
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RANK ligand, at cell ratios of 1:1 and 1:10 (ratio 1:100 was not imaged) (Figure 2.1). 
However, the images do not reveal morphology that allows distinguishing between the 
osteoclast- or osteoblast-like cells. The distribution of fluorescent phosphatases is 
sporadic, with no uniformity for all experimental groups. 
2.3.2 Real-Time PCR 
Osteoblastic differentiation and activity was monitored by the gene expression of 
Runx2, ALP, and osteocalcin. Under osteogenic conditions, Runx2 transcription factor 
for all the cell ratios demonstrated peak expression at Day 22, followed by lower 
expression at Day 29, demonstrating typical cellular differentiation (Figure 2.2A) 
(p=0.0002)). However, at Day 36 expression levels were higher than at Day 29. 
Statistical interaction of medium condition and cell ratio was not evident for Runx2 
expression during the 36 days of culture. Relative expression levels for ALP 
demonstrated no statistical influence by medium conditions; however, cell ratios 
indicated differences in expression levels (Figure 2.2B) (p<0.0001). Cell ratio 1:100 
resulted in significantly higher expression levels as compared to 1:1 and 1:10. OS1 and 
R1 expression levels were lowest for all days as compared to the other ratios. Relative 
expressions at cell ratio 1:100 (OS3 and R3) were lowest at Day 22 with a rise in 
expression for Days 29 and 36 (p=0.0003). For OS1 and OS2, levels were higher at each 
time point while R1 and R2 peaked at Day 29. Osteocalcin expression had no statistical 
interaction with medium conditions and cell ratio groups (Figure 2.2C). Statistical 
analysis indicated no change in expression levels from Day 8 to Day 29, with a higher 
expression at Day 36. Osteopontin expression showed no correlation for different 
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medium conditions; however, cell ratio differences were seen, in which OS1 and R1 were 
higher than other ratios (Figure 2.2D) (p=0.0457).  
Figure 2.2. Relative expression ratio osteoblastic and osteoclastic markers 
of maturation and activation graphed with standard error of mean. Runx2, 
ALP, osteocalcin, and osteopontin are early and late markers for 
osteoblastic characteristics. RANK, NFATc1, and cathepsin K are markers 

































































































































































For osteoclastic differentiation and activity expression levels of RANK, cathepsin 
K, and NFATc1 were observed. The two different medium conditions resulted in similar 
RANK levels; however, there were significant differences between the cell ratios, with 
highest expression for the 1:1 group and lowest expression for the 1:100 group 
(p<0.0001) (Figure 2.2E). NFATc1 gene expression exhibited differences in medium 
conditions (p=0.0041) and cell ratios (p<0.0001) (Figure 2.2F). R medium condition had 
a higher expression of NFATc1 than the OS condition. Unlike the RANK expression, the 
highest NFATc1 expression was exhibited by OS3 and R3 groups, while the lowest was 
seen in the OS1 and R1 groups. The NFATc1 expression levels peaked at 22 days of 
differentiation, then decreased by Day 29. Cathepsin K expression, on the other hand, 
was different within medium conditions; specifically, high levels were evident for the R 
medium condition (Figure 2.2G)(p=0.0041).  
2.3.3 Western Blotting 
Protein production of osteoblastic Runx2 and osteopontin was observed to 
determine differentiation and activation (Figure 2.3). Runx2 production for OS and R 
groups was higher from Day 7 to Day 14; however, at Day 21 the R treatment group 
decreased in production while OS group in all ratios sustained production. In osteopontin 
production, OS ratios increased in production, with Day 21 having the highest while R 






Biomaterials synthesized for bone substitute applications are characterized in 
vitro to determine cellular response and toxicity of the material in culture with bone cells. 
Some groups have co-cultured precursor osteoclasts and osteoblasts to simulate the 
paracrine relationship of the bone cells in regulating bone cell differentiation and bone 
Figure 2.3. Western Blot results for Runx2 and osteopontin production during 
21 days of co-culture. B-actin at day 7 was used as the internal standard. 
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healing [19, 27-29]. However, considerations to the cell ratio of the two precursor cells 
during differentiation were limited or not mentioned at all.  
Osteoclast differentiation depends on the presence of osteoblasts to initiate 
paracrine signaling through membrane-bound receptors (RANK) and ligands (RANK 
ligand). However, the recruitment of precursor osteoblasts to the site of bone resorption 
depends on secreted and membrane-bound factors from osteoclasts. The balance between 
bone resorption and deposition is a coordinated effort to maintain bone integrity and 
health. Increased bone mass leads to osteopetrosis, while decreased bone density causes 
osteoporosis. In healthy bone tissue, histological images reveal that the population ratio 
between osteoclasts and osteoblasts is 1:15 or 1:15.5 [23, 24]. Therefore, it is necessary 
to determine the physiological bone cell ratio for in vitro culture to simulate the 
equilibrium of the bone cells in natural bone tissue in order to establish a co-culture 
system optimal for material characterization.  
A review of the literature reveals the experimental designs have a bias toward 
high osteoclast concentrations in co-culture conditions.  This design allows increased 
resorption on material surfaces which, in turn, leads to more mineral deposition; 
however, the high osteoclast concentration contradicts conditions in native bone. In a 
study conducted by Bernhardt and coworkers, human monocytes and human 
mesenchymal stem cells in a 25:1 ratio were indirectly co-cultured on collagen tapes for 
38 days in RANK ligand-supplemented osteogenic medium. Results showed no 
significant difference in TRAP and Cathepsin K expression between the monoculture 
control and the indirect co-culture, with very little detection of multinucleated cells via 
  
 63 
scanning electron microscopy [29]. Jones and colleagues, on the other hand, conducted 
experiment to compare osteoblast only and osteoclast only culture with co-cultured 
osteoclast (primary murine monocytes) to osteoblast (MC3T3-E1) ratio of 100:1.  The 
cells were seeded on silk fibroin, chitosan films, and poly-l-lactide films to evaluate the 
potential of the material to induce bone resorption. Unfortunately, results from TRAP 
staining for osteoclast differentiation and material surface roughness for osteoclast 
resorption were inconclusive [19]. Using a surface pretreatment approach, Spence and 
coworkers stimulated in vitro osteoclast resorption for 21 days, then removed the 
osteoclasts before seeding osteoblasts onto the resorbed surfaces of hydroxyapatite and 
carbonate-substituted hydroxyapatite discs. Even though the osteoclast to osteoblast cell 
ratio was 100:1 in an indirect co-culture, the results indicated increased collagen 
synthesis for osteoblasts on the resorbed discs [28]. The Tortelli group investigated 3D 
versus 2D co-culture conditions using a 1:1 ratio, under osteogenic conditions, for up to 
60 days. Relative gene expressions and histological results revealed that 3D skelite discs 
stimulated enhanced osteoblast differentiation, leading to early osteoclastic 
differentiation [27]. These studies exemplify the inconsistencies of osteoblast to 
osteoclast cell ratio from study to study and that the studies do not mimic the ratios in 
native bone tissue; therefore, evaluations of material properties and differentiation 
responses are not comparable from laboratory to laboratory and with respect to in vivo 
conditions of bone. Consequently, the need for a standard in vitro culture model, with 
physiologically-relevant precursor osteoclast to osteoblast ratio, is crucial for a 
  
 64 
systematic comparison of materials and simulation of coordinated bone resorption and 
deposition.  
The co-culture of RAW monocytes and D1 stromal cells at three different fixed 
ratios under two osteogenic media conditions was evaluated to determine cell ratio and 
medium parameters for an in vitro co-culture model. Three RAW:D1 precursor osteoclast 
and osteoblast cell ratios, 1:1, 1:10, and 1:100, were chosen with goal of better 
mimicking in vivo conditions for clinically relevant evaluations and predictions. 
Osteoclast activation and osteoblast activity were observed via fluorescence imaging to 
assess multi-nucleation, TRAP granule production, and ALP production. Total RNA was 
collected and analyzed for relative gene expression of markers in osteoclast and 
osteoblast differentiation. 
Positive ELF97 staining for samples in both medium conditions demonstrated the 
presence of endogenous phosphatase from either osteoclast TRAP granules and/or 
osteoblast ALP. In mono-culture of RAW and D1 cells (data not shown), ALP released in 
abundance by D1 cells, while TRAP was limited under osteogenic and growth medium 
conditions. Even with actin and nuclei counterstaining, cell clusters could not be 
distinguished to examine differences in cell morphology. Hence, ELF97 staining and 
counterstaining was not effective for visualizing osteoclast TRAP granules and increased 
ALP production due to the release of ALP from undifferentiated cells. 
To evaluate osteoblast differentiation, expression levels of Runx2, ALP, and 
osteocalcin were measured for stromal cell differentiation and osteoblast mineralization, 
respectively, during 36 days in two osteogenic conditions (OS and R) and with three cell 
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ratios (1:1, 1:10, 1:100). Runx2 is a transcription factor in the signaling pathway directing 
the differentiation of stromal cells into pre-osteoblasts, then into immature osteoblasts; 
however, at later stages Runx2 can hinder osteoblast activity [30, 31]. Hence, a high 
expression of Runx2 during Day 22 of culture, coupled with a lower expression and the 
presence of mature and active osteoblasts at Day 29, indicates differentiation.  
Alkaline phosphatase (ALP) expression suggests immature osteoblasts becoming 
mature osteoblasts, with increasing ALP levels during maturation and plateaus once 
mineralization is initiated. ALP levels for all ratios in both media conditions reached the 
highest by Day 29, indicating a maturation and even activation of osteoblast metabolism. 
The RANK ligand supplemented medium condition induced does not affect osteoblastic 
differentiation according to ALP expression. Cell ratio, on the other hand, does affect 
ALP levels, with OS1 and R1 having the lowest expression while OS3 and R3 have the 
highest, correlating to the presence of differentiated RAW cells. At closer inspection, the 
trough in ALP levels at Day 22 for OS2, OS3, and R3 is unexpected, and possibly 
demonstrates the cyclic nature of ALP activity during osteoblast maturation and 
activation.  
The production of osteocalcin, a calcium-binding protein in osteoblasts, regulates 
mineralization and osteoclast activity; hence, expression levels are expected to be highest 
during mineralization or at the later time points of co-culture. The expression levels 
changed minimally throughout the culture period, with unpredicted peaks on Day 8 for 
OS3 and R3. Osteoclast differentiation is initiated, with monocyte clustering and fusion 
into multinucleated cells through RANK-RANK ligand signaling.  The multinucleated 
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cells are then activated and resorb damaged or old bone by secretion of protolytic 
enzymes [18, 22, 32]. Osteoclast differentiation from RAW monocytes, monitored 
through the expression of membrane receptor RANK, indicates a cell ratio effect. The 
pattern of RANK expression is highest at Day 22, with a lowered expression at Day 29 
and Day 36 rather than a sustained expression of RANK. The lowering of expression at 
Day 29 can be a result of RAW cell fusion or osteoclast apoptosis during osteoclastic 
differentiation; hence, a reduction in overall membrane area for the membrane receptor. 
The downstream signaling of RANK to RANK ligand was measured by expression of 
NFATc1, an early sign of osteoclast differentiation, from Day 8 to Day 22. Hence, 
expression of protolytic enzyme cathepsin K was high on Day 15 and Day 22, suggesting 
resorption as a late marker of differentiation.  
2.5 Conclusions 
The evaluation of early and late differentiation precursor osteoclast and osteoblast 
markers, with goal of establishing a physiological co-culture model of cell ratio for 
precursor bone cell differentiation, demonstrated that high concentration of osteoclastic 
RAW cells can suppress early and late osteoblastic D1 differentiation markers. 
Furthermore, the results provide histomorphological evidence that osteoclast and 
osteoblast population ratio variations can predict healthy and pathological bone 
conditions. During osteoclastic differentiation of RAW cells, early markers directly 
corresponded with RAW concentration while the late marker was higher with respect to 
the RANK ligand condition. Since both osteoclast and osteoblast differentiation and 
activation occurred within 22 days of osteogenic co-culture for both medium conditions, 
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similar to that seen in other in vitro single and co-cultures, the supplementation for 
osteoclastic differentiation in co-culture is nonessential. An in vitro co-culture test system 
for coordinated osteoclast and osteoblast differentiation is necessary to consistently 
characterize cellular response to materials potential under a healthy or diseased 
physiological model. Future studies will focus on confirming precursor cell 
differentiation and activation at the 1:10 cell ratio and will focus on validating the in vitro 
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CHAPTER THREE  
MULTICELLULAR CULTURE TO SIMULATE INFLUENCE OF 
ADIPOCYTES ON THE OSTEOBLAST AND OSTEOCLAST ACTIVITY IN 
VITRO ON 3D BONE GRANULES 
3.1 Introduction 
Patients with bone diseases have the highest risk of sustaining a fracture and have 
high risks of non-unions and mal-unions in fracture healing. Bone diseases are the result 
of hyperactive or hypoactive osteoclasts and/or osteoblasts in bone formation and 
remodeling, leading to bone fragility. The most commonly diagnosed bone disease is 
osteoporosis, with high prevalence in women post-menopause resulting in increased bone 
resorption and thinning of cancellous trabeculae [1-3]. The purported cause of 
hyperactive osteoclast resorption is increased marrow fat due to aging; hence, 
osteoporosis is associated with the obesity of bone [2]. Other bone diseases, such as 
osteopetrosis, abnormal bone growth, and osteogenesis imperfecta, lack of collagen in 
bone formation, are due to genetic mutations and also lead to bone fragility [4, 5]. 
Histomorphometric analysis of patient bone tissue biopsy reveals that osteoblast and 
osteoclast cellular morphology and concentration vary between healthy and diseased 
bone [6-9]. Furthermore, patients with bone diseases undergo bone protective therapy to 
retard bone degeneration via inhibition of osteoblastic bone formation or osteoclastic 
bone resorption. The drug agents systemically target metabolic pathways with a range of 




Current bone fracture management strategies use substitute materials such as 
autografts, allografts, and synthetic tissue to fill the bone fracture void for improved bone 
healing. The demand for engineered bone tissues will increase in the next decade with 
predicted increase of bone fractures due to fragile bone and limited supply of autografts 
and allografts [10]. Bone substitute materials are engineered to mimic gold standard 
autograft biological and mechanical properties. With limitations in exact mimicry, 
engineered substitutes are developed from ceramics, polymers, and their composites to 
induce bone healing and bridge the fracture gap. Commercially available bone substitute 
materials have limited functionality and insufficient accommodation for the pathological 
environment and compromised bone cell activity found in patients with bone diseases. 
Advancements to functionalize material constructs include incorporation of bioactive 
molecules, cytokines, and cellular components to locally stimulate physiological healing 
reaction in healthy and diseased conditions [11-13].  
To complement development of targeted bone constructs, evaluations of the 
materials should be conducted within similar targeted conditions, diseased or healthy, to 
ensure efficacy of construct bioactivity. Hence, in vitro simulation of the bone 
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Figure 3.1. Adipogenic regulation of bone formation and resorption through fatty 
acid and hormonal secretions. 
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parameters such as osteoclast to osteoblast cell population ratio and indirect effects of 
other cell types. The cell population ratio of osteoclast to osteoblast can be determined 
with available clinical histomorphometric data of healthy and diseased bone biopsies [8, 
9]. Understanding the influence of marrow fat adipocytes on bone cell maturation and 
activity can allow mimicry of specific aspects of the disease in vitro [2, 14]. Instead of 
understanding only individual effects of fatty acids and adipogenic hormones at various 
dosages on bone cell functionality, the inclusion of adipocytes is more relevant to 
understanding the synergistic effect of adipogenic regulation of bone metabolism [14-17]. 
Clinical bone density/mass to fat assessment as well as in vitro studies have shown fatty 
acids such as linoleic and stearic can regulate osteoblast mineralization, while adipogenic 
hormonal secretions such as dexamethasone and leptin can regulate osteoclastic 
resorption (Figure 3.1). Quantification of secreted fatty acids from adipocytes and within 
the bone environment has limited precision and reveals no significant differences 
between healthy and diseased bone [16, 18, 19]. 
The purpose of this study was to determine adipocyte influence on co-cultured 
differentiation of precursor osteoclasts and osteoblasts by monitoring gene expression 
and protein production of differentiation and activation markers. The culture system 
included commercially available bone cell-seeded chronOS bone granules in indirect 
contact with adipogenic cells. The healthy bone precursor osteoclast and osteoblast ratio 
was determined in a in Chapter 2 to be 1:10, respectively; this ratio also correlates to 
reported physiological histomorphometric evidence [8, 9]. The goal of this in vitro study 
was to determine if the indirect tri-culture system, combining adipocytes with 
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differentiating osteoclasts and osteoblasts, demonstrated interactions representative of 
diseased conditions without added chemical mediators. That is, the underlying theory was 
that cellular mediators secreted from adipocytes, rather than just fatty acid supplements, 
would have higher physiological relevance. 
3.2 Methods and Materials 
3.2.1 Cell culture 
The culture system was designed to simulate direct interaction of precursor 
osteoclasts and precursor osteoblasts and indirect interaction of the bone cells with 
adipocytes, as shown in Figure 3.2. There are several preparation phases to obtain 
adipocytes to culture with precursor bone cells summarized in the timeline (Figure 3.3).  
To obtain adipogenic cells, D1 cells (200,000 cells per well) (ATCC) were 
differentiated in 12-well plates (Corning) for 14 days in adipogenic medium (10ml 
growth medium ((DMEM) (Atlanta Biologics) supplemented with 10% fetal bovine 
serum (Gibco), 1% penicillin/streptomycin (ATCC), 0.2% fungizone (Invitrogen)) + 
250µl human recombinant insulin (4mg/ml)(Gibco), 2µl dexamethasone (1mg/ml 
Tri-Culture Experimental 
Control Adipogenic 







Figure 3.2. Tri-culture setup with negative control, positive control, and 
experimental group.  
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ethanol)(Sigma), 1ml 5mM 3-isobutyl-1-methylxanthine(Sigma)) prior to tri-culture with 
bone cells.  
The chronOS granules (~300mg, Synthes) were heat sterilized in disposable 
scintillation vials (Wheaton) at 200°C under 10psi in a vacuum oven (VWR Symphony) 
for at least 2 hours. The sterile chronOS granules were transferred to Netwells™ (12-well, 
75µm mesh, Corning) with 2ml of medium (α-MEM, 10% fetal bovine serum, 1% 
penicillin/streptomyocin, 0.2% fungizone) for 2 days. Four days prior to tri-culture, RAW 
264.7 monocytes (ATCC) (1.5x105 cells) and stromal D1 cells (1.5x106 cells) were 
seeded at a 1:10 ratio, respectively, to allow cell attachment and proliferation. 
Differentiation of RAW and D1 cells into osteoclasts and osteoblasts was stimulated with 
osteogenic medium  (Dulbecco’s Modified Eagle’s Medium (DMEM) (Atlanta 
Biologics) supplemented with 10% fetal bovine serum (Gibco), 1% 
penicillin/streptomycin (ATCC), 0.2% fungizone (Invitrogen), 0.1µM dexamethasone 
(Sigma), 10mM β-glycerophosphate (Sigma), 5µg/ml ascorbic acid (Sigma)). Controls 
were differentiated in mono-culture for adipocytes and co-culture for RAW:D1 cells.  
Adipogenic Differentiation of D1s 
Culture of 
RAW:D1 
Tri-culture under osteogenic conditions 
Differentiation of RAW:D1 to OC:OB 
Day -10 Day 4 Day 8 Day -3 Day 14 Day 0 
Tri-culture 
Figure 3.3. Timeline for tri-culture, with differentiation phase for adipogenic 




To initiate tri-culture, Netwells were transferred to appropriate well compartments 
for the tri-culture experimental, control osteogenic, control adipogenic, and negative 
undifferentiated control for 2 weeks of tri-culture (Figure 3.2). Samples (n=3) were 
collected at Days 4, 8 and 14 for protein and ribonucleic acid (RNA) extraction to 
analyze gene expression of differentiation markers with real-time polymerase chain 
reaction (PCR) and protein production via Western Blot. Samples were also collected for 
Western Blotting to determine protein production of Runx2, osteopontin, and RANK. 
Table 3.1. RT-PCR Primers 
Primers Sequence Reference 
Internal Standard 
 GAPDH F 5’-GAACGGATTTGGCCGTATTG-3’  
[20]  R 5’-CGTTGAATTTGCCGTGAGTG-3’ 
Osteoblast Early Differentiation Marker 
 Runx2 F 5’-AGTGGACCCTTCCAGACCAG-3’  
 R 5’-TAATAGCGTGCTGCCATTCG-3’  
 ALP F 5’-GTAACGGGCCTGGCTACAAG-3’  
 R 5’-AAAGACCGCCACGTCTTCTC-3’  
Osteoblast Late Differentiation Marker 
 Osteocalcin F 5’-TGCGCTCTGTCTCTCTGACC-3’  
 R 5’-ATGGAAGGCTAAGGGCTCTG-3’  
 Osteopontin F 5’-AAAGAGAGCCAGGAGAGTGCC-3’  
  R 5’-TGTGGCTGTGAAACTTGTGGC-3’  
Osteoclast Multinucleation 
 RANK F 5’-GGACGTTCACACTGGTCAGC-3’  
 R 5’-TGCTTCCCTGCTGGATTAGG-3’   
 NFATc1 F 
5’-CTCGAAAGACAGCACTGGAGCAT-
3’  
[21]  R 5’-CGGCTGCCTTCCGTCTCATAG-3’ 
Osteoclast Resorption 
 Cathepsin K F 5’-CTGCCTTCCAATACGTGCAG-3’   
 R 5’-CCTTTGCCGTGGCGTTATAC-3’  
Adipocyte Marker  
 PPARγ2 F 5’- CTCCGTGATGGAAGACCACTC -3’  
 R 5’- AGCAACCATTGGGTCAGCTC-3’  
 AP2 F 5’- AGCCCAACATGATCATCAGCG -3’  
 R 5’-TCGAATTCCACGCCCAGTTTG-3’  
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3.2.2  RNA isolation 
At Days 5 and 14 of the tri-culture, samples were collected for RNA isolation 
using Trizol Reagent (Invitrogen) per manufacturer’s instructions under the 600 PCR 
Workstation (AirClean Systems). Briefly, culture medium was aspirated from well plates 
before 1ml of TRIzol reagent was added. The well plates with TRIzol were placed on a 
plate rocker (VWR Minishaker) for 5 minutes at 200rpm to obtain cell lysates from 
within the crevices of the chronOS granules. Lysates were transferred to a 1.5ml RNase-
free centrifuge tube (Fisher Scientific) before 0.2ml of chloroform  (Honeywell HPLC 
grade) was added to  
dissolve RNA into the aqueous phase. The aqueous layer was transferred to a new 
tube and 0.5ml of isopropyl alcohol (VWR) was added to precipitate the RNA. The RNA 
was sequentially washed with 75% ethanol (Sigma). The ethanol was removed, the RNA 
was allowed to air dry to remove most of the excess ethanol, then the RNA was dissolved 
in 30µl of nuclease-free water (Promega). Removal of DNA contaminants was performed 
on the RNA samples using the TURBO DNase-Free kit (Ambion). Quantification and 
qualification of the RNA samples were conducted using the NanoDrop 2000 
spectrophotometer (Thermo Scientific), then samples were stored at -80°C until reverse 
transcription.  
3.2.3 Reverse transcription and real time PCR 
Reverse transcription with heat denaturation was performed as instructed in the 
RETROscript kit (Ambion) with 436µg of RNA samples (amount was limited by RNA 
collected). QuantiTect SYBR Green kit (Qiagen) was used to perform real-time PCR 
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with primers (Runx2, alkaline phosphatase (ALP), osteocalcin (OCN), osteopontin 
(OPN), RANK, cathepsin k (Cap K), and NFATc1) obtained from Integrated DNA 
Technologies. The StepOne Plus (Applied Biosystems) was used to maintain a holding 
temperature of 95°C for 15 minutes, then to provide 35 denaturation cycles at 94°C for 
15 seconds, annealing at 54°C 20 seconds, and extension at 72°C for 20 seconds. Melting 
was conducted at a 70-99°C ramp to check for primer-dimers. The cycle number (Ct) was 
obtained at a threshold of 0.1 to calculate relative expression ratios (RER) of target genes 
compared to the internal standard GAPDH, using the ΔΔCt method.  
The RER were analyzed via JMP 10 (SAS) to determine significant mean 
differences and interactions (p ≤ 0.05) for osteoclast and osteoblast differentiation 
markers at various maturation stages.  
3.2.4 Western blotting 
To quantify protein production of Runx2 and osteopontin, Western blotting was 
performed on isolated protein samples. Protein was isolated using 150µl of Mammalian 
Protein Extraction Reagent (MPER; Pierce, Thermo Scientific) per sample using an 
ultrasonicator (Sonic Dismembrator, Fisher Scientific) for two 3s cycles. The lysate was 
collected and centrifuged for 5 minutes at 14,000rpm, then stored at -4°C. Bicinchoninic 
acid (BCA) protein assay (Pierce, Thermo Scientific) was performed to quantify total 
protein concentration per sample for gel electrophoresis. Total protein (20µg) was diluted 
with 6x Laemmli sample buffer and distilled water for a total volume of 45µl, and loaded 
onto 12-well 10% Tris-HCl Criterion gels (Bio-Rad). Proteins on the gel were blotted 
onto a 0.45µm nitrocellulose membrane for protein detection. Primary antibodies for 
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osteopontin (66kDa) and Runx2 (55kDa) (Rabbit-anti-mouse, Santa Cruz), followed by 
secondary goat-anti-rabbit conjugated with horseradish peroxidase, (HRP) were used to 
detect protein at specific molecular weights. Beta-actin (42kDa) conjugated with HRP 
(Cell Signaling) was used as the internal standard. Chemiluminescence imaging was 
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Tri-Culture Osteoblastic Differentiation Markers  
Day 4 Day 8 Day 14 
Figure 3.4. Osteoblastic gene expression for early and late differentiation markers. No 
differences in expression were detected between control and tri-culture group for 
Runx2 and ALP. Osteocalcin expression was higher for control group than for tri-
culture group (p=0.428). Osteopontin expression for control and tri-culture groups was 




Gene expression was assessed to monitor differentiation of precursor osteoclastic 
RAW cells and precursor osteoblastic D1 stromal cells in indirect contact with 
adipocytes. No difference was detected in early-stage osteoblast differentiation genes 
when comparing osteogenic control and tri-culture through 14 days (Figure 3.4). No 
change was detected in Runx2 levels for either group over 14 days, while ALP 
expression peaked at Day 8 for the control group. Significant differences (p=0.0428, 
p=0.0001, respectively) were detected in osteocalcin and osteopontin, later markers of 
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Tri-Culture Osteoclastic Differentiation Markers  
Day 4 Day 8 Day 14 
Figure 3.5. Osteoclastic gene expression of differentiation markers. A correlation 
was detected between expression levels and study groups for RANK (p=0.0001) and 
cathepsin K (p=0.044). Results show no statistically significant relationship between 
downstream transcription factor NFATc1 and study groups. 
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group expressed higher levels of osteocalcin after Day 8. Osteopontin levels in the tri-
culture system increased throughout the 14-day study, while control levels peaked at Day 
8.  
Lower levels of RANK and cathepsin K, osteoclastic markers, were detected in 
tri-culture at Day 8 (p=0.0001; p=0.004) (Figure 3.5). However, the levels of downstream 
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Figure 3.6. Adipogenic gene 
expression of differentiation 
markers. Control cultures 
expressed higher levels of 
PPAR-γ (p=0.004) and AP2 
(p=0.0001) as compared to tri-
cultures. Tri-cultures exhibited 
a sustained expression of 
PPAR-γ while control 
expression decreased. Both 
conditions showed decreased 




Adipogenic characteristics were monitored through the production of PPAR-γ and 
AP2 (Figure 3.6). PPAR-γ expression in the control group decreased after Day 4, while 
the level in the tri-culture group plateaued throughout 14 days of the study (p=0.004). 
AP2 expression behavior for both groups similarly decreased throughout the study; 
however, levels were higher for the control group at Day 4 (p=0.0001) (Figure 3.6).  
Protein production of Runx2 and osteopontin, measured by Western Blot, 
indicated differences among all groups during the 14-day experiment. Runx2 for the tri-
culture condition was higher than the positive control at Day 4, while minimal production 
was evident for the negative control (2D growth).  Protein concentration of Runx2 
Figure 3.7. Western Blot for 
protein production of Runx2 
and osteopontin during14 day 
tri-culture (Tri) with positive 
(Con) and negative (Neg) 
controls. Production of Runx2 
and osteopontin are higher in 
tri-culture as compared to in 
Neg. Tri-culture levels of 
Runx2 are greater but the 
levels of osteopontin are 
















decreased with time in the osteogenic control and tri-culture conditions, similar to what 
one would expect in vivo. Osteopontin production, on the other hand, was produced in 
sustained fashion for all 14 days of tri-culture, similar to production patterns in the 
positive control. Osteopontin was produced minimally in the negative 2D control as 
compared to production in osteogenic conditions.  
3.4 Discussion  
One hypothesized cause of osteoporosis is the accumulation of marrow fat in 
aging, resulting in increased bone resorption and eventually low bone mass [19]. Hence, 
women who inherently have higher body fat have higher accumulation of marrow fat 
post-menopause and are predisposed to osteoporosis. However, a deeper understanding of 
the mechanisms of osteoporosis is necessary to improve preventative measures and 
pathological understanding of the condition. Even though clinical evidence from several 
studies reveals no significant differences in fatty acids between patients with normal and 
osteoporotic bone, researchers are curious about the orchestration between adipogenic 
and osteogenic cells [2, 15, 22]. In vitro studies have been designed to understand 
lipotoxicity and adipogenic regulation of bone cell metabolism; however, co-cultures 
with either osteoblastic or osteoclastic cells on a two-dimensional (2D) environment 
exemplify limited understanding of a disease or condition [16, 17, 23, 24]. The inverse 
relationship of osteogenesis and adipogenesis can be monitored by the expression of early 
and late markers like PPAR-γ and Ap2, respectively. Elbaz and coworkers studied 
primary human osteoblasts and osteoclasts in 2D for 21 days and observed lipotoxicity of 
stearate and palmitate, resulting in a decrease in osteoblast differentiation and activation 
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markers (Runx2, ALP, OCN) [16]. Similar results were observed by Liu and coworkers 
in their investigation of PPAR-γ and adiponectin regulation of osteoblastic differentiation 
[24]. As for adipogenic regulation of osteoclastogenesis, the Kunh and colleagues and 
Hozumi and colleagues confirmed both positive and negative effects on differentiation 
and activity with direct and indirect cultures [17, 24].  
Studies in the literature have suggested the inverse relationship between 
adipogenesis and osteogenesis as a hypothesis for osteoporosis pathogenesis. However, 
as demonstrated clinically, cell population ratios also influence cellular activity [8, 9]. 
Indeed, the indirect tri-culture with adipogenic cells demonstrated influence of fat on 
osteoblast activation and osteoclastogenesis. Statistical analysis revealed no differences 
in osteoblast expression of transcription factor Runx2 or ALP, indicators differentiation. 
However, Runx2 production measured via Western Blot was higher in tri-culture 
conditions; it is known that mineralization of osteoblasts can be hindered due to 
excessive Runx2 signaling [25]. Osteocalcin and osteopontin expressions were higher in 
the control groups, suggesting suppressed osteoblastic activity in the tri-cultures. On the 
contrary, no difference was seen between osteopontin production in the control group and 
that in the tri-culture group. Osteoclast maturation and activation, confirmed via RANK 
and Cathepsin K levels, were also retarded by adipogenic presence during the 14-day 
culture period. Interestingly, the decrease in PPAR-γ evident in the control conditions is 
phenotypic once stromal cells commit to adipogenic lineage, while sustained levels 
PPAR-γ exhibited in the tri-culture condition suggested indirect regulation of adipogenic 
maturation by soluble factors from co-cultured osteoclastic and osteoblastic cells. 
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Expression difference of AP2 further supports the theory that communication within the 
tri-culture condition is bi-directional.  
3.5 Conclusion 
Soluble cytokines and factors produced by adipocytes, osteoblasts, and osteoclasts 
orchestrate the differentiation and activation within a tri-culture condition. Adipocytes 
suppress both late osteoblast maturation and mineralization and down-regulate osteoclast 
differentiation and resorption activity. Adipogenic activity is altered in tri-culture 
conditions as compared to mono-culture conditions. Recognizing the complex 
communication pathways between adipocytes, osteoblasts, and osteoclasts, an in vitro 
test system with clinical relevance can be established to model osteoporosis and 
characterize bone substitute materials for patients with bone diseases. By further altering 
the adipocyte:osteoblast:osteoclast cell ratio, a deeper understanding of pathological-like 
activity can be realized and used to evaluate the effectiveness of bone substitute materials 
in targeting fragility fractures. 
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CHAPTER FOUR  
A LOOK AT BIOMEDICAL ENGINEERING PRINCIPLES AND MEDICAL 
DEVICES THROUGH BONE DISEASES AND BONE IMPLANTS 
4.1 Introduction 
Within biomedical engineering (BME), there are multiple concentrations/foci 
requiring a variety of engineering and science expertise and collaboration. Medical 
device technologies developed by biomedical engineers range from imaging machines (x-
ray, magnetic resonance) to diabetic monitors to pacemakers to bandages. The focus of 
this teaching module is on bone tissue engineering, in which engineers/scientists 
strategize to resolve complications in bone healing, bone fractures, and bone diseases 
with medicinal agents, medical devices, and engineered tissue or substitute materials. 
Hence, bone tissue engineering is an interdisciplinary field of biology, anatomy and 
physiology, chemistry, mechanical engineering, physics, and material science. The 
introduction of BME through implementation of this bone fracture education module will 
demonstrate to the students the core ideas of engineering design and practices according 
to the Next Generation Science Standards (NGSS). The education module distills BME 
concepts, with focus on bone tissue engineering, into a 1-hour demonstration with a 
hands-on activity of simulated bone and bone implants that is easily translated to a 
classroom setting for all grade levels. The presentation introducing BME, bone biology, 




x) and can be tailored for a specific grade level according to NGSS performance 
expectations.  
Bone implant design is a relatable example as children are at risk for bone 
fractures, leading to casting for simple fractures and bone implants and surgery for 
complex fractures. Depending on the location of the complex fracture, bone implants can 
be a system of screws and plates (long bones), intramedullary nails (long bones), rods and 
screws (spine), and joint replacements (knees and hips). Bone implants are devices used 
to mend two pieces of bone, and are similar to hardware supplies used to build a house. 
Plates and nails/screws are used to join to planks of wood in fixed fashion, while hinges 
and screws are used in joints on doors to allow movement. The material, size, and shape 
of the plates, screws, and hinges depend on such factors as the type of wood, the load the 
house frame needs to support, the forces that the house frame will encounter. Similarly, 
factors such as age, health, and gender will influence implant selection for a patient. 
Many implants are designed to be removed following bone healing. For example, if a 
child receives an implant, such as screws and plates, to mend a complex fracture in the 
humerus, the screws and plates will likely be removed once the fracture is healed to allow 
further bone growth and avoid bone deformity.  
The module will allow students to experience the process of implant development 
– designing, testing, redesigning – and determine necessary features for a successful bone 
implant system to accommodate the clinical need, patient specifications, and surgical 
feasibility. The long bone fracture is simulated using cardboard tubes as cortical bone for 
shape similarity and accessibility while the styrofoam and foam insulation represents 
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cancellous/spongy bone (Figure 4.1). As the students learn about BME, they should also 
understand that medical device design means balancing requirements in various criteria: 
• Biology Criteria 
o Supports the body and/or body functions 
o Causes minimal to no immune response 
o Causes no further damage  
• Patient Criteria 
o Accommodates all sizes and shapes 
o Allows quick recovery  
o Promotes good healing 
o Minimizes costs after insurance 
• Surgeon Criteria 
o Facilitates minimal surgical trauma 
o Accommodates short implantation time 
o Comprises minimal parts or pieces 
o Has low chance of failure 
In house construction, the location (geographic region, immediate surroundings), 
the budget, and the potential homebuyer preferences determine the type of material, the 
architecture, and the foundation.  That is, the home should withstand weather conditions, 
be aesthetically pleasing, and be accommodating.   
Even though an engineer can have the best design to address the biology criteria, 
if the implant does not meet the surgeon’s criteria, then it is a failure. The process of 
commercializing an implant takes years due to testing, retesting, and approval 
procedures. An engineer designing a biomedical product, such as a bone implant, must 
wear a variety of thinking caps in order to meet the demands of the customers (the 
patients and surgeons). Therefore, during the hands-on activity or the engineering 
challenge, inquiry questions (Table 4.1) stimulate students to seek different answers 
depending on the cap they are wearing. Follow-up questions are asked that lead the 
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students to think about compromises and compare the importance of one criterion against 
the other.    
4.2 Understanding Bone Function and Physiology 
The 206 bones in the adult skeleton provide protection for the internal organs, 
support to keep the body upright, and movement at joints. Without the skeleton, the body 
would be floppy skin, organs, and muscles, found in a pile on the ground, unable to 
withstand gravity. The architecture of bone is a complex network of trabeculae, even 
more advanced and geometrically efficient than the scaffolding of the tallest skyscraper. 
The synergistic combination of inorganic (hydroxyapatite) and organic (collagen) 
components gives bone high compressive and tensile strength, respectively. Cortical, or 
compact, bone has higher compressive strength than cancellous, or spongy, bone; hence, 
cortical bone is arranged on the exterior of the bone while cancellous bone is on the 
interior. The spongy interior of long bone serves as a storage and source for bone marrow 
rich in essential red and white blood cells.  
Bone has the unique ability to heal minor bone defects without leaving a scar; that 
is, bone continuously remodels and repairs small unnoticeable damages a person might 
sustain. Unfortunately, bone diseases and complex fractures do occur, leading to 
compromised or no healing. One of the most common bone diseases worldwide is 
osteoporosis, or low bone mass, which decreases the mechanical strength of bone. Since 
many patients with bone diseases develop brittle bone, they have the highest risk for 
fractures. Biomedical engineers have been designing and redesigning bone implants to 
resolve this problem.  
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When a person breaks a bone, the doctor evaluates the fracture to categorize it to 
ensure the best treatment for good bone healing. The preferred treatment would be a 
simple external cast made of plaster, but for patients with complex fractures, internal 
fixation with implants is necessary to realign the bone. For patients with bone diseases, 
such as osteoporosis, the brittle bone can be damaged with the implantation of a screw or 
other implants, leading to a fracture. Some engineers have recognized this design 
problem and are focused on balancing the biological and mechanical criteria for bone 
implants. Commercially available plate and screw options include titanium, stainless 
steel, and cobalt alloys; the selected system must allow mechanical strength to support 
body weight while the fracture heals. Clinically, a plate is implanted to hold the fractured 
bone in place; screws are placed some distance away from the fracture gap, at varying 
angles, to stabilize the plate.   
During design and development of bone implants, engineers brainstorm to 
consider implant material, chemistry, implant shape, implant mechanical and biological 
properties (compressive strength, manufacturability, biocompatibility), clinical 
application, ease of implantation, and fracture site. Once a product design is 
conceptualized, a prototype is produced for testing to optimize implant properties and 
eliminate possible failures. If the design survives testing and the clinical approval 
process, the time from concept design to commercialization is years. This hands-on 
activity allows students to implant plates and screws using a simulated fracture of normal 
and osteoporotic bone and demonstrates the engineering design process, from prototype 
to testing to redesigning, for bone with biological and mechanical differences. 
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4.3 Education Module Implemented at Girl Scout Event 2013  
A BME education module was developed to implement at a 1-day event that 
focused on introducing various engineering and science fields to a group of ~50 girl 
scouts (6th – 8th grade) from the Upstate region of South Carolina. The BME module was 
one of three science or engineering modules, each geared toward hands-on and 
interactive teaching. Before the demonstrations started, the girls were split into three 
groups to rotate through each module during the day.  
For each group of girls, the bone implant demonstration started with a 
presentation to introduce BME, bone biology, bone mechanics, bone health, and fracture 
treatments. The presentation was interactive; the girls were encouraged to respond to 
Table 4.1 Questions Focused on Engineering Practices 
Interactive Presentation 
What is biomedical engineering? 
What are the functions of bone? 
What bone are the two types of bone? 
Who has had a broken bone? 
How does broken bone heal? Is it different for children and adults? 
What are the problems of bone disease? 
How was your bone stabilized to heal? 
What are the differences and similarities of this broken bone model to real broken bone? 
What are the limitations of the model? 
Are the materials used a good representation of bone? 
What part of the bone does the cardboard/styrofoam represent? 
Why is metal the material of choice for bone implants? 
Hands-on Activity 
Think like an 
engineer 
 
What material would you use? Plastic or metal? 
How many plates/screws would you use? 
Where would you put the plates/screws? 
What material would you use for the osteoporosis fracture? Why? 
If the implant can fail, how do you think it will fail? 
How can you calculate the forces in the mechanical testing? 
If you were performing this surgery on a real person, how could you 
limit the surgery time? 
Think like a 
surgeon 
How many implants would you use? 
How many screws would you use? 
Does the implant need to be clean before it is implanted? 
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questions listed in Table 4.1 during the appropriate times. The girls were asked if they 
had ever broken a bone or if they knew anyone who had; they were then asked how that 
fracture was treated and if there were complications with healing. The presentation then  
 
transitioned into methods of treating bone fractures, with details on bone implant devices 
and designs. During the implant design discussion, the girls were asked what 
characteristics and considerations would benefit a bone implant. Once they had defined 
the problem and brainstormed some design criteria, a humerus fracture was introduced as 
the engineering challenge. The girls were given the activity kit and the tools to start their 
implantation, which included two models of bone fractures (normal and osteoporotic, 
Figure 4.1). The girls observed the differences in the color and the hardness of the two 
broken bone models. To stimulate their engineering thinking, the girls were asked what 
material they would use as an implant for the normal and osteoporotic bone (Figure 4.2). 
Figure  4.2. Components of the bone implant kit for two 




After the girls finished their implant (Figure 4.3), they performed bend, torsion, tension, 
and compression tests to observe the changes and failures with their designs (Figure 4). 
Testing was the best part for the girls since they were allowed to attempt to break what 
they just designed and fixed. 
For the bend test, the girls oriented their fixed bone model horizontally and bend 
the model holding the two bone segments. For the torsion test, the girls twisted the two 
bone segments in different directions. For the tension test, the girls pulled their two bone 
segments apart. Lastly, for the compression test, the girls placed their bone models on 
end on the ground, placed a large cardboard tube (2 feet tall) around the model, and 
dropped dumbbell weights (3, 5, and 8 pound weights) down the tube, on top of the bone 
model, to test how much load their plate and screw setup could support. Groups that 
Figure 4.3. Example of fracture repair of 
simulated bone fracture with ~1 inch gap for testing. 
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finished first had time to redesign and retest their implant systems. The girls had an 
opportunity at the end of the session to summarize their findings to the rest of the class 
and suggest improvements to their design for both the normal bone and osteoporotic 
bone. The girls were able to take their bone implants home to remind them about 
biomedical engineering.        
 To gauge the girls’ attitudes towards math, science, and engineering, before and 
after the events of the day, survey questions were posed targeting the girls’ interest in, 
value of, and confidence toward the three fields. The questions followed the Likert Scale, 
with a 5-point rating scale ranging from 1 as “strongly disagree” to 5 as “strongly agree”. 
Pre- and post-surveys with similar questions were given to students at the beginning and 
end of the day, respectively, to measure changes in the students attitudes towards math, 
science, and engineering. The survey data showed that the interest, perceived value, and 
self-confidence with respect to science and engineering statistically increased over the 
course of the 1-day event. 
4.4 Attitude Survey Assessment 
To gauge the girls’ attitudes towards math, science, and engineering, before and 
after the events of the day, survey questions were posed targeting the girls’ interest, 
value, and confidence of the three fields. Questions for the survey were revised from 
those published by Gibbons and colleagues to measure middle school students’ attitude 
and knowledge about engineering [1]. The questions followed the Likert Scale, with a 5-
point rating scale ranging from 1 as “strongly disagree” to 5 as “strongly agree”. Pre- and 
post-surveys with similar questions were given to students at the beginning and end of the  
  
 96 
day, respectively, to measure changes in the students attitudes towards math, science, and  
engineering. Data distribution was expected to be skewed and nonparametric; hence, the 
Table 4.2 Pre- and Post- Survey Results for Girls Scout Event 
Category Question n p-value 
Interest 
I like math 33  
I like science 33 0.0325 
I like engineering 33 0.0005 
Task Value 
It is important for me to learn math 33  
It is important for me to learn science 32 0.0181 
It is important for me to learn engineering 33 0.0041 
Confidence 
I am good at math 33  
I am good at science 33  
I am good at engineering 33 0.0044 
I can be a mathematician 32  
I can be a scientist 33  
I can be an engineer 33  
Expected 
Outcomes 
Mathematicians help people 32  
Scientists help people 33  
Engineers help people 33  
Values indicate significant positive change (Pre-Post) 
Table 4.3 Pre- and Post- Survey Results for STEM Day Event 
Interest 
I am interested in math  
I am interested in science  
I am interested in engineering p=0.0005 
I want to learn more math in college  
I want to learn more science in college  
I want to learn more engineering in college p=0.002 
Task Value 
Math will be important for my future  
Science will be important for my future  
Engineering will be important for my future p=0.0005 
Confidence 
I am good at math  
I am good at science   
I am good at engineering p=0.0027 
I have the skills to be a mathematician p=0.0039 
I have the skills to be a scientist p=0.0156 
I have the skills to be an engineer p=0.0191 
Expected 
Outcomes 
Mathematicians help solve society's problems  
Scientists help solve society's problems  
Engineers help solve society's problems  
Values indicate significant positive change (Pre-Post) 
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Wilcoxon Signed Rank test nonparametric data analysis for matched pair changes was 
employed for each question using statistical software JMP 10 (Table 4.2 and 4.3). Total  
sample size was n=45; however, the usable sample number was reduced to n=33 or 32 
due to missing “pre” or “post” survey answers for the Girl Scouts and n=24 for the 
juniors. The survey data showed that the interest, perceived value, and self-confidence 
with respect to science and engineering increased over the course of the 1-day event. 
Furthermore, the positive attitude changes for juniors in high school during this science, 
technology, engineering, and mathematics (STEM) awareness, 1-day event indicates an 
immediate impact on students of varying grade levels.   
4.5 Materials and Assembly 
Supplies per student will cost ~$5 for 80 or more students. Preparation and 
assembly are required prior to activity (Table 4.4). To make the simulated normal bone,  
Table 4.4 Materials List and Feasible Substitutes 
Materials Specifications Supplier 
Paper cylindrical tubes Light-Duty Paper Tubes, 2”x20”, 0.0045” thick - 23612 www.yazoomills.com 
Styrofoam poles Extruded Styrofoam poles, 2”x36” www.thecraftplace.com 
Great Stuff™ insulating 
foam Insulating foam sealant- gaps, cracks Lowes 
Metal mending plates The Hillman Group 0.5” x 4.5” x0.35” Lowes 
Plastic mending plates* Similar to metal plates Special made with laser cutter 
Screws The Hillman Group, 100 count 8x 3/4 zinc plated metal screw Lowes 
Equipment Substitutes Purpose 
Band saw Hand held saw Cut tubes into fragment sections 
Drill press Apple corer and hammer Hollow out center of foam 
Phillips screw driver  Tighten screws 
Nail Push pin Make hole for screws 
Weights – 2,5,8 lb Heavy books Test the implants 
*Substitutes: plastic screws, different metal plates, different thickness metal plates, or none 
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insert the styrofoam pole into the cylindrical tube and cut into 2” segments, then hollow 
out a 1” diameter hole in the center. The osteoporotic bone segment is made by spraying 
insulation foam into the tube and allowing the foam to cure overnight. Once the foam has 
set, hollow out the center like the normal bone (Figure 4.1). Assemble the kits with the 
components as shown in Figure 4.2, targeting two students per kit.  
The list of materials includes the basic suggestions that can be expanded upon to 
challenge the students or make the activity more specific to the classroom. Variation in 
the plates and screws would address the engineering process more as the students interact 
with common materials in uncommon conditions (Table 4.4). 
4.6 Hands-On Activity Setup 
After present the background on the activity, the students had an opportunity to 
look at their activity kit to discuss and assess their plan of construction. In groups of two, 
the students will choose and help each other to either repair the normal or osteoporotic 
fracture. Once the fracture has been repaired (Figure 4.3), students will make 
observations and predictions about their implant properties then conduct mechanical tests 
(Figure 4.4). The students will perform a bend, torsion, tension, and compression test 
with a one-inch gap between the two bone segments, similar to actual test setup and 
testing conducted on actual plate and screw bone implant system. The compression 
testing will be the most destructive test, with the heaviest weight causing implant failure. 
After testing, students will record what they observed through testing, noting the possible 




4.7 Teaching Assessment 
The education module and activity will allow teachers to implement the eight 
practices of engineering and practices from the Framework for K-12 Science Education: 
Practices, Crosscutting Concepts, and Core Ideas (2012) by the National Research 
Council. Teachers can stimulate questions (Table 4.1) as they present the module and the 
activity. As the bone fracture scenario is presented to the students, they can practice their 
writing in defining the medical problem and devising solutions. They can do so 
individually then discuss with their partner for different ideas and share their 
interpretation of the bone model. Even though the plates and screws are provided, both 
teachers and students can still be creative in the materials and implementation as 
Figure 4.4. Schematic of the bend, torsion, tensile, 




summarized in Table 4.5. For example, if students are given two plates, some will decide 
to use one and other decide to use two. However, with two plates students can stack them 
together to increase the thickness and possible the mechanical strength or place the plates 
with distance apart. Typically students will want to drill the screws straight into the bone 
model but they can also try to angle the screws for stability at various angles. Students 
are also challenged to think differently for the osteoporotic bone versus the normal bone 
in consideration for the change in bone mechanical properties. 
Table 4.5 Variations in Fracture Fixation 
Plates Screws Materials 
Angle Angle  Metal  
Displacement (if 
more than one) Displacement Plastic 
Length Length Wood  
Quantity Quantity 
 Thickness Threading 
Width Diameter 
 
The questions, listed on Table 4.1, can be modified to become assessment or 
evaluation questions that can focus on one particular subject area within the 
multidisciplinary field of BME. For example, in a biology class, teachers can expand 
upon the components of bone, the growth of bone, the healing reaction of bone, the 
functions of bone, compatibility of materials to the body. For a physics class, the teachers 
can focus on the mechanics (forces, stresses, momentum, etc.) of bone from the micro-
scale of trabeculae in long bone to macro-scale of the bone and joints in abduction and 
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adduction. In a chemistry class, students can learn about material science of metals, bone 
matrix composition, and the sterilization procedure of implants.  
Before students begin the activity they can assess the materials they have and plan 
out their initial design. Students can then write down their predictions, observations, and 
results from the mechanical testing to evaluate for the redesigning of the plates and 
screws to increase the mechanical stability of the implant system for both the normal and 
osteoporotic bone model. Observations of implant failure during the mechanical can be 
quantitative for math-based classes or qualitative for biological classes. Calculations of 
load on bone for various body types and locations in the body and forces from the 
compression testing to understand the restrictions of the design and improve on the 
redesign. Students can then evaluate the data and observations to explain why the implant 
was failing to reassess their model and alter their design with different ideas. At the end 
of the module, students can present their findings, complications, and successes to the 
rest of the class. At the end, the students should relate to the boarder impact of 
engineering design and problem solving to help society such as biomedical engineering in 
solving health problems through advanced medical devices.  
4.8 Modifications to Meet Education Standards Specific to Grade Groups 
This teaching module can more details on bone implants, bone physiology, and 
bone diseases in accordance to the Disciplinary Core Ideas of Progression to increase the 
sophistication of student critical thinking (Table 4.6). Teachers can incorporate all or 




Table	  4.6	  Tailoring	  the	  Presentation	  and	  Activity	  to	  Incorporate	  Core	  Ideas	  


















Atomic	  structure	  of	  plastic	  
and	  metal	  plates	  and	  
screws	  
Mechanical	  properties	  due	  to	  
atomic	  structure	  of	  different	  
plastics	  and	  metals	  
Different	  forces	  
bones	  can	  handle	  




Stability	  of	  the	  implant	  
system	  with	  different	  plate	  
and	  screw	  lengths	  and	  
displacement	  	  
Defect	  propagation	  of	  plastics,	  
metals,	  and	  bone	  to	  cause	  
failure	  
	   	  
Transfer	  of	  body	  weight	  
onto	  the	  implant	  
Chemical	  properties	  of	  metal	  
and	  plastic	  
	  
Erosion	  of	  metals	  in	  the	  body	  
due	  to	  micro-­‐motion	  
Forces	  (stress	  and	  strain)	  
transmitted	  to	  plates	  and	  
screws	  
Potential	  and	  kinetic	  energy	  
supported	  by	  the	  implant	  
Motion,	  energy,	  and	  forces	  in	  








	   Functions	  of	  arms	  
and	  legs	  





Structure	  and	  composition	  
of	  bone	  (organic,	  inorganic	  
minerals,	  cells)	  
Function	  of	  bone	  cells	  in	  
maintaining	  bone	  health	  and	  




Growth	  of	  body	  
with	  a	  focus	  on	  
bone	  
Functions	  of	  bone	  
Causes	  of	  bone	  diseases	  due	  













	   Introduction	  of	  
medical	  devices:	  
bone	  implants	  	  
Difference	  
between	  bone	  
and	  bone	  implant	  	  
Function	  of	  bone	  implant	  
in	  healing	  
Examples	  of	  various	  bone	  
implants	  differing	  in	  design	  
Treatment	  
methods	  for	  bone	  
fractures	  
Biological	  design	  
criteria	  of	  bone	  
implant	  
Clinical	  criteria	  for	  bone	  
implants	  
Examples	  of	  biomedical	  
technologies	  used	  to	  better	  
quality	  of	  life	  for	  the	  users	  
Importance	  of	  
implant	  to	  help	  
bone	  heal	  
	  
Importance	  of	  biomedical	  





























Development	  of	  healthy	  
bone	  
Bone	  diseases	  in	  older	  
population	  and	  female	  
population	  
Aging	  of	  bone	  	   Aging	  of	  bone	   Treatments	  for	  bone	  diseases	  
Diseases	  of	  bone	   Diseases	  of	  bone	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CHAPTER FIVE  
CONCLUSION 
The advancement of tissue engineering and regenerative medicine will rely on the 
development of bioactive tissue substitutes with specificity for diseases and effectiveness 
in pathological conditions. In bone tissue engineering, strategies are focused on localized 
delivery of bone protective agents via bone substitute biomaterials; surface coatings on 
internal implants improve integration and reduce osteolysis. To predict clinical outcome 
of these innovative designs, devices and matrices must undergo sophisticated in vivo and 
clinical testing. However, the fundamental in vitro testing system can also be as 
sophisticated with elevated mimicry of the physiological and pathological bone 
environment. Establishing in vitro culture systems focused on standard parameters of cell 
population ratio, seeding order, and soluble mediators for native bone metabolism will 
allow for screening of the effectiveness of tissue engineered designs. Various 
investigations to characterize bioactivity of bone substitute constructs have used mono- 
and co-cultures; however, culture parameters such as cell population ratio and 
differentiation supplements are unconsidered and inconsistent. The objective of the 
proposed work is to establish the parameters for cell ratio determination, using RAW 
monocytes and D1 stromal cells and osteogenic conditions, with or without RANK ligand 
supplements to induce osteoclastogenesis.  Specifically the objective was to pinpoint 
those cultures that demonstrate phenotypic gene expression during differentiation 
towards osteoclasts and osteoblasts on a 3D bone substitute material. To further simulate 
the natural bone environment, the co-culture parameters in a tri-culture system allowed 
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the evaluation of the paracrine effect of adipocytes on osteoclast catabolic and osteoblast 
anabolic metabolism in remodeling.  
The first two aims of the project focused on evaluating osteoblastic and 
osteoclastic differentiation, with varying cell population ratio, on a 3D bone environment 
to emphasize the balance in bone metabolism. Furthermore, the influence of RANK 
ligand on induction of osteoclast differentiation was assessed. Gene expression indicated 
cell ratio as a variable in regulating osteoblastic mineralization with no effect on 
maturation while regulating osteoclastogenesis with no effect on activation of osteoclasts. 
The coordination of osteoclastic and osteoblastic differentiation and activation at the 1:10 
ratio is comparable to clinical observations derived from normal bone biopsy 
histomorphometry. As for RANK ligand addition to induce osteoclast differentiation and 
maturation, the relationship was not statistically significant in co-culture with precursor 
osteoblasts, the native producer of RANK ligand. In addition, Western blot results 
indicate that the addition of RANK ligand hinders production of differentiating and 
mineralizing proteins in osteoblasts. Hence, the use of RANK ligand should be avoided 
to minimize inhibition of osteoblastic activity. Within a co-culture system of precursor 
osteoclasts and osteoblasts, the cell population ratio needs careful consideration in order 
to appropriately mimic relevant aspects of physiological and pathological conditions.  
The chance of the reported clinical failure of chronOS in treating a patient with 
scoliosis could have been significantly reduced by screening for bioactivity using a co-
culture in vitro system with a 1:1 osteoclast to osteoblast ratio. The use of normal 
progenitor cells at an abnormal ratio would simulate scoliosis with normal bone 
  
 107 
conditions, an imbalance in bone catabolism, and anabolism during spinal development. 
At the 1:1 test system ratio, early osteoblastic differentiation was lower on chronOS 
while early osteoclastic differentiation was higher. Minimal osteoblastic migration and 
abnormal osteoclastic multinucleation can lead to no bone formation or resorption, as 
seen on the explant.  
To understand the regulatory influence of adipocytes on the differentiation of 
bone cells, a tri-culture system was designed to allow indirect co-culture of bone cells 
with adipocytes. Results indicated that the presence of adipocytes hindered osteoclastic 
maturation and activity while only affecting the mineral deposition of osteoblastic cells 
and not the early maturation. The tri-culture system can be applied as an osteoporotic test 
system or can be applied to other disease environments, with variations in cell ratio and 
cell types. The characterization of bone constructs in advanced in vitro test systems at the 
early stage of development can facilitate the inexpensive prediction of biological failures 
before in vivo testing. Hence, developing the tri-culture system to be more clinically 
relevant will improve the ability to predict bone construct bioactivity in an in vivo 
environment. 
For diseases in which bone cell activity is abnormal, further considerations are 
necessary. The in vitro systems can become complex with four or more cell types and 
even inclusion of inflammation conditions; however, in vitro test system design should be 
simple and yet mimetic to provide a quick pass/fail preliminary screen that leads to 
continued in vivo testing or to selection of a new material. 
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The fourth aim of this research project focused on introducing biomedical 
engineering to middle and high school students with a teaching module about bone 
implants, bone biology, and engineering design. The teaching module was implemented 
at a Girl Scout event for middle school girls and a Science, Technology, Engineering and 
Mathematics event for high school juniors. Students were encouraged to be curious and 
creative during the presentation and hands-on activity, as the differences and importance 
in bone health regarding the simulated bone fracture were presented. They also learned 
about the differences in fracture management in which implants are the last resort. In 
their design of the implants, students gained understanding of the difficulty of implanting 
the bone screws and plates on even the simulated bone. During the testing of their fixed 
fracture, the students were reminded that the most important part of engineering design is 
to avoid implant failure for patients. Survey results demonstrated that the teaching 
modules with the incorporated bone implant lesson positively influenced both the middle 
school students and high school juniors in their understanding of engineering, their 
confidence to succeed in engineering, and the importance of engineering for society.  
In conclusion, the research overall exemplified the need for culture test systems to 
be as sophisticated as the materials being investigated. In advancing understanding of 
pathological conditions and simulation of physiological conditions, fundamental in vitro 
evaluations of engineered bone devices can screen for potential incompetencies. 
Characterization of bone constructs can target different pathological conditions to 
examine specificity of bioactive molecules, cytokines, and nano-particles supplemented 
on the devices. The long-term goal is to significantly improve characterization of 
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technologies for pathological fractures by incorporating human mesenchymal and 
hematopoietic stem cells from bone aspirates in normal and pathological co-culture and 
tri-culture systems. Hence, results from this research will impact the advancement of 
bone tissue engineering strategies by answering the increasing demands for efficiency in 
engineered bone tissue and internal fixation devices. Awareness of the implications of 
bone diseases can be disseminated to young students or future engineers with this unique 
workshop that incorporates bone biology with fixation implant designs.   
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CHAPTER SIX   
RECOMMENDATIONS FOR FUTURE WORKS 
1. For clinical relevance, allografts can be obtained to co-culture cells and compare 
with other commercially available bone constructs. It will be important to ensure 
that all parameters are the same and all materials are sterilized according to 
company standards.  
2. Once optimized, protective bone agents can be tested to understand coupling 
inhibition or induction responses by both osteoclasts and osteoblasts for local 
dosage determination and long-term systemic effects. 
3. For clinical relevancy, the cell ratio study and the tri-culture study should be 
conducted using primary human cells. However, the test system should be 
optimized for murine and human cells for labs that have no access to primary 
cells. 
4. The tri-culture can be advanced into other models of pathological bone, modeling 
with respect to the adipocytes, etc. Further characterization of the tri-culture will 
be necessary to establish it as a osteoporotic model.  
5. For a more extensive understanding of osteoclastic and osteoblastic activity, a 
longer differentiation/maturation period for tri-culture is recommended. In 
addition, determine if adipogenic communication with bone cells affects activity 
with tri-culture of differentiated osteoclasts and osteoblasts.  
6. Since tri-culture for bone cells are on a 3D bone matrix, adipocyte differentiation 
should be conducted on a 3D hydrogel matrix to increase physiological relevance. 
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However, attention should be paid to potential interactions of soluble factors 
between bone cells and fat cells.  
7. Experiments should be conducted to determine different methods of measuring 
osteoclastic activity. One approach would be to assess the protease activity of 
cathepsin K or matrix metallopeptidase 9 (MMP-9) using zymography. Due to the 
3D environment of the bone constructs, TRAP staining cannot be performed; 
additionally, the use of ELF97 is general for all endogenous phosphatases.  For 
these reasons, ELISAs will need to be implemented to assess osteoclastic activity. 
The TRAP ELISA was conducted, but it did not detect any of the samples 
collected. 
8. An alternative to visually qualify osteoblasts and osteoclasts on the substitute 
materials is to trypsinize or isolated the mature/active cells from the material to be 
plated on tissue culture plastic well plates. Realize that this procedure will alter 
cellular behavior, morphology, and population. 
9. To measure adipogenic activity, a triglyceride assay and gas chromatography 
should be conducted to evaluate secreted fatty acid in the medium. Oil red O stain 
can be conducted for adipocytes in 2D culture but, for 3D culture, a different 
imaging method should be used.  
10. Depending on the bone construct, measurement of calcium phosphate and other 
mineral deposition may not be possible with a chemical assay. One alternative is 
to use energy-dispersion x-ray (EDX) via scanning electron microscopy (SEM). 




11. To improve upon the teaching model to make it more accessible for teachers and 
instructors, plates should be revised using household items or items that are 
commercially available.  
12. The styrofoam for the normal cancellous bone can be changed to something less 
dense and stiff so that students can more easily insert screws. Also the 
incorporation of a hollow styrofoam will eliminate the necessity to drill a hole 
inside the tube.  
13. Survey questions should be altered to focus on just the bone implant lesson to 
gain more insight on the effectiveness of the module in introducing biomedical 
engineering and engineering design. However, the lesson itself then needs to be 
expanded upon to be more than an hour to complement the entirety of the survey. 
14. A follow up student event should be developed to reinforce the initial information 




















Comparison of differentiation in mono-culture; D1 and RAW cells differentiating into 
osteoblasts and osteoclasts, respectively, on 2D well plate and 3D chronOS granules at 
Day 14. Samples were collected at Days 4, 8 and 14. 
a)   b)   
c)  
Figure A1. Fluorescent images 
of mono-culture of D1 cells under (a) 
negative control (only growth medium), 
(b) 2D osteoblastic differentiation with 
osteogenic medium, and (c) 3D 
osteoblastic differentiation with 
osteogenic conditions. Cells were 
probed with Hoechst nuclear stain 
(blue), AlexaFluor 546 actin stain (red), 






Gene	  Expression	  and	  Significance	  
Marker	   Time	   Matrix	   Time*Matrix	  
ALP	   0.0025	   -­‐	   -­‐	  
Runx2	   0.0160	   -­‐	   -­‐	  
OCN	   0.0025	   0.0102	   0.0180	  
CapK	   <0.0001	   -­‐	   0.0403	  
RANK	   0.0121	   0.0087	   0.0144	  
























Mono-culture Osteoblastic Differentiation 






















Mono-culture Osteoclastic Differentiation  




Bone Implant Teaching Module 
The presentation is accessible through DropBox: 
https://www.dropbox.com/s/uwk7qfpzzed5khb/Biomedical%20Engineering%20Worksho
p.pptx 
To modify presentation, enter password: BME 
The presentation includes instructions, notes, and suggestions for teachers to modify to 





















Survey Questions given to the Girl Scouts in middle school and Juniors in high school: 
Please	  check	  one	  box	  for	  each	  statement.	  
	   Strongly	  Disagree	   Disagree	  
No	  
Opinion	   Agree	  
Strongly	  
Agree	  
I	  like	  math	   	   	   	   	   	  
I	  like	  science	   	   	   	   	   	  
I	  like	  engineering	   	   	   	   	   	  
It	  is	  important	  for	  me	  to	  
learn	  math	   	   	   	   	   	  
It	  is	  important	  for	  me	  to	  
learn	  science	   	   	   	   	   	  
It	  is	  important	  for	  me	  to	  
learn	  engineering	   	   	   	   	   	  
I	  am	  good	  at	  math	   	   	   	   	   	  
I	  am	  good	  at	  science	   	   	   	   	   	  
I	  am	  good	  at	  engineering	   	   	   	   	   	  
I	  can	  be	  a	  mathematician	   	   	   	   	   	  
I	  can	  be	  a	  scientist	   	   	   	   	   	  
I	  can	  be	  an	  engineer	   	   	   	   	   	  
Mathematicians	  help	  
people	   	   	   	   	   	  
Scientists	  help	  people	   	   	   	   	   	  
Engineers	  help	  people	   	   	   	   	   	  
 
Open-­‐ended	  questions:	  
What	  do	  mathematicians	  do?	  
What	  do	  scientists	  do?	  	  
What	  do	  engineers	  do?	  
How	  do	  mathematicians	  help	  people?	  
How	  do	  scientists	  help	  people?	  
How	  do	  engineers	  help	  people?	  
	  
Additional	  questions	  given	  on	  post-­‐survey	  (with	  rating	  scale) 
I	  learned	  what	  electrical	  engineers	  do	  
I	  will	  tell	  my	  friends	  and	  family	  about	  what	  I	  learned	  in	  electrical	  engineering	  class	  
I	  learned	  what	  mechanical	  engineers	  do	  
I	  will	  tell	  my	  friends	  and	  family	  about	  what	  I	  learned	  in	  mechanical	  engineering	  class	  
I	  learned	  what	  bioengineers	  do	  
I	  will	  tell	  my	  friends	  and	  family	  about	  what	  I	  learned	  in	  bioengineering	  class	  
 
